{"text": "The glimepiride group had a similar improvement in the mean HOMA - B value to 68 % from a baseline value of 43 % .No improvement in HOMA - B was observed in the placebo group ; baseline and end - of - study values were 45 and 43 % , respectively .", "label": "", "metadata": {}, "score": "26.776005"}
{"text": "For the effect of liraglutide on heart rate compared with placebo , the I 2 value was 55 % .However , this value reduced to 0 % when the data from a single trial ( LEAD-1 ) were withheld .", "label": "", "metadata": {}, "score": "31.13202"}
{"text": "The majority ( 65 % ) of the randomly assigned subjects were treated with two OADs before the study .Efficacy .Within the first 12 weeks of the study , mean A1C values for the overall population decreased from baseline for all liraglutide treatment groups and for the glimepiride group whereas a slight increase was observed in the placebo group ( Fig . 1 A ) .", "label": "", "metadata": {}, "score": "31.851603"}
{"text": "The majority ( 83 % ) of the randomized subjects were treated with two or more OADs before the study .Efficacy .At the end of the study , the mean A1C values for the overall population decreased by ( means \u00b1 SE ) 1.5 \u00b1 0.1 % for both 1.2 and 1.8 mg / day liraglutide groups and 0.5 \u00b1 0.1 % for the placebo group .", "label": "", "metadata": {}, "score": "32.105797"}
{"text": "Statistical analysis .Pretrial calculation showed that a two - sided test of the highest dosage versus the placebo group required 30 patients per group to detect a difference in mean HbA 1c of at least 1 % unit with 5 % significance and 95 % power .", "label": "", "metadata": {}, "score": "34.793083"}
{"text": "Approximately half of the liraglutide group were able to lose at least 7 % of baseline weight compared with 4 % in the placebo group .", "label": "", "metadata": {}, "score": "35.69508"}
{"text": "Slight increases in pulse rate were observed in all treatment groups ( 2 - 3 bpm in the liraglutide groups and 1 bpm in the glimepiride and placebo groups ) .", "label": "", "metadata": {}, "score": "36.76674"}
{"text": "A total of 22 studies provided heart rate data .Overall , GLP-1 agonists produce a significant increase in heart rate with a weighted mean difference of 1.86 bpm ( 0.85 to 2.87 ) versus placebo and 1.90 bpm ( 1.30 to 2.50 ) versus active control .", "label": "", "metadata": {}, "score": "38.010315"}
{"text": "Effect on glycemic control .After 12 weeks of treatment , HbA 1c was decreased in all groups except the lowest liraglutide dosage group ( Fig . 1 A ) .", "label": "", "metadata": {}, "score": "38.45454"}
{"text": "The only potential adverse change in Table 2 was an increase in pulse seen with liraglutide treatment compared with placebo .Additional adverse events are detailed in the Supplementary Table .", "label": "", "metadata": {}, "score": "38.698067"}
{"text": "RESULTS -A total of 190 patients were included in the intention - to - treat ( ITT ) analysis .HbA 1c decreased in all but the lowest liraglutide dosage group .", "label": "", "metadata": {}, "score": "38.82705"}
{"text": "In addition , a loss of 7 % of baseline weight occurred significantly more often in those receiving liraglutide ( 54 vs. 4 % ) , and a loss of 10 % of baseline weight was seen only in the liraglutide - treated group ( 17 % ) .", "label": "", "metadata": {}, "score": "39.411877"}
{"text": "As was seen with HbA 1c , fasting serum glucose levels decreased in most treatment groups during the trial , with the decreases being statistically significant for the 0.225- , 0.60- , and 0.75-mg liraglutide dosage groups compared with placebo ( Table 2 ) .", "label": "", "metadata": {}, "score": "39.586617"}
{"text": "Overall , GLP-1 agonists produce a significant increase in heart rate with a weighted mean difference of 1.86 bpm ( 0.85 to 2.87 ) versus placebo and 1.90 bpm ( 1.30 to 2.50 ) versus active control .", "label": "", "metadata": {}, "score": "39.915184"}
{"text": "RESULTS .Baseline characteristics of the study population are provided in Table 1 .There were no significant differences among subjects randomly assigned to exenatide or placebo for the first treatment period .", "label": "", "metadata": {}, "score": "40.321198"}
{"text": "Greater percentages of subjects receiving prestudy monotherapy achieved the target compared with their respective counterparts receiving prestudy combination therapy ( 66 and 39 % , respectively , for 1.8 mg liraglutide ) ( compare Fig .", "label": "", "metadata": {}, "score": "40.46866"}
{"text": "The postprandial values of the 1.8 mg liraglutide group also appeared to be similar to those of the glimepiride group and less than those of the placebo group .", "label": "", "metadata": {}, "score": "41.3582"}
{"text": "The purpose of this study was to evaluate the effect of liraglutide treatment compared with matching placebo injections in older ( mean age , 58 \u00b1 8 years ) overweight / obese individuals with prediabetes - those at highest risk for development of T2DM and CVD .", "label": "", "metadata": {}, "score": "41.368797"}
{"text": "RESEARCH DESIGN AND METHODS We randomized 68 older individuals ( mean age , 58 \u00b1 8 years ) with overweight / obesity and prediabetes to this double - blind study of liraglutide 1.8 mg versus placebo for 14 weeks .", "label": "", "metadata": {}, "score": "41.569504"}
{"text": "Geometric mean- estimated repeated - measurement analysis showed calcitonin levels of 0.89 , 0.83 , and 0.75 ng / l for 1.2 mg liraglutide , 1.8 mg liraglutide , and placebo , respectively , at the end of the study ( all values within the normal range ) .", "label": "", "metadata": {}, "score": "41.765205"}
{"text": "CONCLUSIONS -In subjects with type 2 diabetes , once - daily liraglutide induced similar glycemic control , reduced body weight , and lowered the occurrence of hypoglycemia compared with glimepiride , when both had background therapy of metformin .", "label": "", "metadata": {}, "score": "42.34184"}
{"text": "Data from the LEAD trials of liraglutide 57 , 64 , 67 , 69 , 73 were initially grouped into quartiles of baseline heart rate and demonstrated significant variations in effect between these subgroups , with the greatest increase seen in those with the lowest baseline values .", "label": "", "metadata": {}, "score": "42.93244"}
{"text": "Overall , GLP-1 agonists increased the heart rate by 1.86 beats / min ( bpm ) ( 95 % CI 0.85 to 2.87 ) versus placebo and 1.90 bpm ( 1.30 to 2.50 ) versus active control .", "label": "", "metadata": {}, "score": "42.981384"}
{"text": "Overall , GLP-1 agonists increased the heart rate by 1.86 beats / min ( bpm ) ( 95 % CI 0.85 to 2.87 ) versus placebo and 1.90 bpm ( 1.30 to 2.50 ) versus active control .", "label": "", "metadata": {}, "score": "42.981384"}
{"text": "Overall , GLP-1 agonists increased the heart rate by 1.86 beats / min ( bpm ) ( 95 % CI 0.85 to 2.87 ) versus placebo and 1.90 bpm ( 1.30 to 2.50 ) versus active control .", "label": "", "metadata": {}, "score": "42.981384"}
{"text": "Although difficult to directly compare , the improvement in glycemia in the liraglutide - treated subjects appear better than reported with weight loss alone in the prediabetes population ( 5 , 7 , 21 ) .", "label": "", "metadata": {}, "score": "43.1287"}
{"text": "Differences between liraglutide and placebo groups were assessed using independent t test or \u03c7 2 test .Mean differences within groups were tested using paired t tests .", "label": "", "metadata": {}, "score": "43.13852"}
{"text": "Safety .The percentages of subjects withdrawn because of adverse events were generally greater in the liraglutide groups than in the glimepiride or placebo groups ( Table 1 ) .", "label": "", "metadata": {}, "score": "43.282883"}
{"text": "Sixty - nine individuals qualified for the study .One individual withdrew from the study before randomization .Therefore , 24 individuals randomized to liraglutide and 27 individuals assigned to placebo completed testing at the end of the study and were included in the analyses .", "label": "", "metadata": {}, "score": "43.36129"}
{"text": "Patients were randomly assigned to one of five fixed - dosage groups of liraglutide ( 0.045 , 0.225 , 0.45 , 0.60 , or 0.75 mg ) , placebo , or open - label sulfonylurea ( glimepiride , 1 - 4 mg ) .", "label": "", "metadata": {}, "score": "43.500565"}
{"text": "For example , the benefits of weight loss in the prediabetes population have been demonstrated in large clinical trials ( 4 - 7 ) .In these studies , loss of 5 - 7 % of baseline weight with diet modification and exercise prevented the development of T2DM in individuals with prediabetes .", "label": "", "metadata": {}, "score": "43.97818"}
{"text": "Pratley R , Nauck M , Bailey T , et al .One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin , both in combination with metformin , in patients with type 2 diabetes : a randomised , parallel - group , open - label trial .", "label": "", "metadata": {}, "score": "43.98653"}
{"text": "We have derived a similar effect size to a previously reported value for weight loss , 2 although our study has distinguished between placebo and active comparators , in which effects sizes differ substantially .", "label": "", "metadata": {}, "score": "44.061867"}
{"text": "For the heart rate effect of liraglutide versus placebo , the heterogeneity was largely attributable to a single trial ( LEAD-1 ) , but the cause of the higher heart rate effect in this trial is unclear .", "label": "", "metadata": {}, "score": "44.22158"}
{"text": "HOMA ( 22 ) was used to assess \u03b2 - cell function and insulin resistance after 12 weeks of liraglutide treatment .Mean \u03b2 - cell function ( derived from fasting insulin and glucose ) was significantly higher in the 0.75-mg liraglutide group after 12 weeks than in the placebo group ( Table 2 ) .", "label": "", "metadata": {}, "score": "44.6444"}
{"text": "Statistical analysis .Our study was powered to assess the primary outcome of change in body weight during exenatide treatment .We calculated that we needed 42 subjects to detect a ( mean \u00b1 SD ) 2.6 \u00b1 1.3 kg difference in body weight between exenatide and placebo treatment at 16 weeks with 80 % power and an \u03b1 value of 0.05 .", "label": "", "metadata": {}, "score": "45.124527"}
{"text": "CONCLUSIONS .Liraglutide therapy in combination with metformin and TZD provided significant decreases in A1C , FPG , and PPG with weight loss ; decreases in SBP ; and a low rate of minor hypoglycemia .", "label": "", "metadata": {}, "score": "45.608566"}
{"text": "In addition , 75 % of individuals treated with liraglutide achieved normal fasting glucose compared with 19 % on placebo .A recent meta - analysis of randomized clinical trials has demonstrated a consistent pattern of modest weight loss and improved glycemic control and cardiometabolic risk factors in patients with T2DM treated with GLP-1 receptor agonists ( 9 ) .", "label": "", "metadata": {}, "score": "45.71486"}
{"text": "There were 4.1 and 6.7 % of subjects treated with 1.2 and 1.8 mg liraglutide and positive for liraglutide antibodies at the end of the study ( versus none with placebo ) .", "label": "", "metadata": {}, "score": "46.446022"}
{"text": "Patients were instructed to maintain their diet , exercise program , and daily routines during the course of the trial .After a 4-week wash - out period during which current oral hypoglycemic agent ( OHA ) treatment was discontinued , patients were equally randomized to double - blind treatment of one of six arms ( one of five dosages of liraglutide or placebo ) or to the open - label reference group ( glimepiride ) .", "label": "", "metadata": {}, "score": "46.52555"}
{"text": "Thus , addition of once - daily liraglutide to metformin monotherapy is a viable treatment option if weight gain and hypoglycemia are a concern .A1C profiles for the overall study population ( A ) , for subjects with prestudy oral monotherapy ( B ) , and for subjects with prestudy oral combination therapy ( C ) .", "label": "", "metadata": {}, "score": "46.65319"}
{"text": "FPG values decreased within 2 weeks of randomization with liraglutide , remaining relatively stable thereafter , while with placebo , smaller decreases occurred ( Fig . 1 C ) .", "label": "", "metadata": {}, "score": "46.659885"}
{"text": "Insulin resistance ( measured by HOMA - IR ) was reduced in all three treatment groups but was not significantly different between groups .No significant differences in the change - from - baseline of HOMA - IR and fasting insulin and glucagon values were observed between either of the liraglutide groups versus the placebo group ( Table 2 ) .", "label": "", "metadata": {}, "score": "46.87019"}
{"text": "The trial was double blind for the five dosage levels of liraglutide and placebo , and open label for glimepiride .The blinding was kept until database release .", "label": "", "metadata": {}, "score": "47.1386"}
{"text": "Most gastrointestinal events were transient ( i.e. , they resolved within 1 - 3 days ) .Side effects within the gastrointestinal system are known to occur after GLP-1 treatment and seem to be dosage related ( 14 , 28 , 29 ) .", "label": "", "metadata": {}, "score": "47.18928"}
{"text": "Results are described using the random effects approach due to the heterogeneity of the included studies .Analyses were stratified by active control or placebo .", "label": "", "metadata": {}, "score": "47.33811"}
{"text": "1 E and F ) .The percentages of subjects in the 1.2 and 1.8 mg liraglutide treatment groups achieving the ADA and AACE A1C goals were comparable to the percentage achieving goals in the glimepiride group .", "label": "", "metadata": {}, "score": "47.709488"}
{"text": "Buse JB , Klonoff DC , Nielsen LL , et al .Metabolic effects of two years of exenatide treatment on diabetes , obesity , and hepatic biomarkers in patients with type 2 diabetes : an interim analysis of data from the open - label , uncontrolled extension of three double - blind , placebo - controlled trials .", "label": "", "metadata": {}, "score": "47.762558"}
{"text": "Subjects taking metformin at enrollment could go through a modified titration period or advance directly to the metformin maintenance period .Glimepiride ( active and placebo ) was taken orally once daily in the morning .", "label": "", "metadata": {}, "score": "47.775642"}
{"text": "At the highest dosage levels , there was a trend toward improved HbA 1c with duration of treatment .Furthermore , treatment with liraglutide caused no weight increase , and , at the highest dosage , the difference with glimepiride was statistically significant .", "label": "", "metadata": {}, "score": "47.95587"}
{"text": "Gastrointestinal adverse events were more common with liraglutide , but most occurred early and were transient .CONCLUSIONS Liraglutide combined with metformin and a thiazolidinedione is a well - tolerated combination therapy for type 2 diabetes , providing significant improvements in glycemic control .", "label": "", "metadata": {}, "score": "48.0672"}
{"text": "This current trial is part of a phase 3 clinical development program for liraglutide .The trial investigates whether glycemic control ( measured by A1C ) achieved by type 2 diabetic subjects using combination therapy of liraglutide and metformin is significantly better than that achieved with metformin monotherapy or at least as good as that achieved with combination therapy of metformin and glimepiride .", "label": "", "metadata": {}, "score": "48.409813"}
{"text": "Such improvements in \u03b2 - cell function have the potential to delay type 2 diabetes progression .The liraglutide - treated subjects generally had improvements in glycemic parameters ( decreases in A1C , FPG , and postprandial glucose from baseline ) similar to those of glimepiride - treated subjects .", "label": "", "metadata": {}, "score": "48.433174"}
{"text": "\u03b2 - Cell function , as determined by HOMA analysis , was significantly improved at the highest liraglutide dosage compared with placebo .There was no effect on the \u03b1 - cells in the fasting state , in so far as the glucagon concentrations were unaltered .", "label": "", "metadata": {}, "score": "48.679634"}
{"text": "This finding probably results from the addition of liraglutide as a second therapeutic agent in subjects whose type 2 diabetes may not be as advanced as that is those subjects entering the study with prestudy combination therapy .", "label": "", "metadata": {}, "score": "48.752758"}
{"text": "Change from baseline in glucose level variability and hypoglycaemia at baseline , weekly during liraglutide dose escalation , at 12 weeks pre - transplant , at 24 weeks post - transplant , 52 weeks post - transplant and 56 weeks ( 4 weeks after withdrawal of liraglutide or liraglutide placebo ) .", "label": "", "metadata": {}, "score": "48.827713"}
{"text": "Of these , four were excluded because the comparator was another form of GLP-1 .25 - 28 In three cases , the doses were not as specified in our inclusion criteria , 29 - 31 and in a further two , the study involved further analysis of data from trials that were already included .", "label": "", "metadata": {}, "score": "48.892662"}
{"text": ": the LEAD-1 SU Study Group .Liraglutide , a once - daily human GLP-1 analogue , added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes ( LEAD-1 SU ) .", "label": "", "metadata": {}, "score": "48.917816"}
{"text": "In this study , patients with type 2 diabetes who meet randomization criteria will be randomized to either liraglutide or placebo , with serial assessment of beta - cell function over 48 weeks follow - up .", "label": "", "metadata": {}, "score": "48.927956"}
{"text": "Apovian CM , Bergenstal RM , Cuddihy RM , et al .Effects of exenatide combined with lifestyle modification in patients with type 2 diabetes .", "label": "", "metadata": {}, "score": "49.08243"}
{"text": "No formation of antibodies toward liraglutide was detected after 12 weeks of treatment .The sensitivity of the assay has been found to be 30 ng / ml ( data on file ) using a monoclonal antibody .", "label": "", "metadata": {}, "score": "49.175987"}
{"text": "BMJ Open 2013;3:e001986 .Page 16 . greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes ( Lead 1-SU ) .", "label": "", "metadata": {}, "score": "49.2866"}
{"text": "Pratley RE , Nauck M , Bailey T , et al .Liraglutide vs sitagliptin for patients with type 2 diabetes who did not have adequate glycemic control with metformin : a 26 week , randomised , parallel group , open - label trial .", "label": "", "metadata": {}, "score": "49.401527"}
{"text": "The latter trial was conducted in patients with poorly controlled HbA 1c levels , indicating that the GLP-1 treatment concept may be applied to a wide range of glycemia in type 2 diabetes .", "label": "", "metadata": {}, "score": "49.42814"}
{"text": "Significantly better glycaemic control and weight reduction with liraglutide , a once - daily human GLP-1 analog , compared with insulin glargine : all as add - on to metformin and a sulphonylurea in type 2 diabetes ( Abstract ) .", "label": "", "metadata": {}, "score": "49.53772"}
{"text": "There was no lifestyle intervention .The primary outcome was change in body weight .RESULTS Subjects treated with exenatide lost an average of 2.49 \u00b1 0.66 kg compared with a 0.43 \u00b1 0.63 kg weight gain during placebo treatment .", "label": "", "metadata": {}, "score": "49.681126"}
{"text": "Ratner RE , Maggs D , Nielsen LL . , et al Long term effects of exenatide therapy over 82 weeks on glycemic control and weight in overweight metformin treated patients with type 2 diabetes mellitus .", "label": "", "metadata": {}, "score": "49.685425"}
{"text": "Patient - reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy : results from a randomized controlled trial in patients with type 2 diabetes .", "label": "", "metadata": {}, "score": "49.717785"}
{"text": "The decreases in SBP in the 0.6 mg liraglutide and placebo groups were 0.6 and 1.8 mmHg , respectively .On the basis of the SBP and weight profiles over time , the reduction in SBP may not be fully explained by the reduction in body weight .", "label": "", "metadata": {}, "score": "49.825317"}
{"text": "Higher attrition in the placebo group Robinson LE , Holt TA , Rees K , et al .BMJ Open 2013;3:e001986 .doi:10.1136/bmjopen-2012 - 001986 5 Meta - analysis of effects of GLP-1 on heart rate , blood pressure and body weight .", "label": "", "metadata": {}, "score": "49.83613"}
{"text": "In addition , several studies have shown GLP-1 to have an appetite - reducing effect ( 8 - 10 ) , and one study has demonstrated weight loss after treatment with GLP-1 ( 11 ) .", "label": "", "metadata": {}, "score": "50.177383"}
{"text": "Russell - Jones D , Cuddihy RM , Hanefeld M , et al .Efficacy and safety of exenatide once weekly versus metformin , pioglitazone , and 65 . sitagliptin used as monotherapy in drug - na\u00efve patients with type 2 diabetes ( DURATION-4 ) : a 26-week double - blind study .", "label": "", "metadata": {}, "score": "50.30104"}
{"text": "One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin , both in combination with metformin , in patients with type 2 diabetes : a randomised , parallel - group , open - label trial .", "label": "", "metadata": {}, "score": "50.376884"}
{"text": "Bergenstal R , Lewin A , Bailey T , et al .Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea .", "label": "", "metadata": {}, "score": "50.57151"}
{"text": "In addition to augmented weight loss and enhanced insulin sensitivity , the results in Table 2 show that liraglutide treatment was associated with improvement in some CVD risk factors .", "label": "", "metadata": {}, "score": "50.581562"}
{"text": "This study assessed the efficacy and safety of liraglutide after 12 weeks of treatment in type 2 diabetic patients .RESEARCH DESIGN AND METHODS -A double - blind , randomized , parallel - group , placebo - controlled trial with an open - label comparator arm was conducted among 193 outpatients with type 2 diabetes .", "label": "", "metadata": {}, "score": "50.60057"}
{"text": "( 18 ) evaluated the impact of acute infusion of GLP-1 in healthy , young , normal - weight men and found no effect on peripheral insulin sensitivity as measured by the hyperinsulinemic - euglycemic clamp .", "label": "", "metadata": {}, "score": "50.819935"}
{"text": "As such , the occurrence of nausea did not appear to account for the weight loss .No significant differences in the change - from - baseline fasting insulin and fasting C - peptide values were observed between the liraglutide treatment groups compared with either the glimepiride or placebo groups .", "label": "", "metadata": {}, "score": "50.917656"}
{"text": "Peripheral insulin resistance was directly measured with the modified version ( 13 ) of the insulin suppression test at baseline and after 14 weeks of liraglutide or placebo .", "label": "", "metadata": {}, "score": "50.933723"}
{"text": "CONCLUSIONS .Incretin mimetics are quickly gaining popularity for the treatment of type 2 diabetes .Exenatide is associated with a reduction in hemoglobin A1C of 0.5 - 0.8 % and liraglutide with a reduction of 1.1 - 1.5 % ( 11 - 14 , 17 ) .", "label": "", "metadata": {}, "score": "50.934196"}
{"text": "Where SDs for the outcome were not available , they were imputed according to the Cochrane Handbook for Systematic reviews V.5 .Heterogeneity was estimated using the \u03c7 2 test and I 2 statistic .", "label": "", "metadata": {}, "score": "51.07156"}
{"text": "Bergenstal RM , Wysham C , MacConell L , et al .Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes ( DURATION-2 ) : a randomised trial .", "label": "", "metadata": {}, "score": "51.157356"}
{"text": "Kim D , MacConell L , Zhuang D , et al .Effects of once - weekly dosing of a long - acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes .", "label": "", "metadata": {}, "score": "51.194702"}
{"text": "Approximately two - thirds of the gastrointestinal events reported during treatment with liraglutide were resolved within 1 - 3 days .None of the patients withdrew due to gastrointestinal events ( Table 1 ) .", "label": "", "metadata": {}, "score": "51.258415"}
{"text": "Nauck M , Frid A , Hermansen K , et al .Efficacy and safety comparison of liraglutide , glimepiride and placebo , all in combination with metformin in type 2 diabetes .", "label": "", "metadata": {}, "score": "51.426743"}
{"text": "Davies M , Pratley R , Hammer M , et al .Liraglutide improves treatment satisfaction in people with type 2 diabetes compared with sitagliptin , each as an add on to metformin .", "label": "", "metadata": {}, "score": "51.535843"}
{"text": "Other potential sources of het- erogeneity include the characteristics of background OAD treatments common to both arms as these treat- ments differed between trials .For the heart rate effect of liraglutide versus placebo , the heterogeneity was largely attributable to a single trial ( LEAD-1 ) , but the cause of the higher heart rate effect in this trial is unclear .", "label": "", "metadata": {}, "score": "51.682728"}
{"text": "The trial was explained to all patients , and their written informed consent was obtained before any trial - related procedures were initiated .For patient safety , an upper limit for HbA 1c was defined as a 4-week wash - out period and a placebo arm was included in the trial .", "label": "", "metadata": {}, "score": "51.71031"}
{"text": "Another recent liraglutide phase 3 study demonstrated that a subgroup of subjects previously treated with diet and exercise and then treated with 1.8 mg liraglutide monotherapy had a mean A1C decrease of 1.60 % that was sustained over the 52-week trial period .", "label": "", "metadata": {}, "score": "51.74154"}
{"text": "Comparison groups(s ) : Comparators included placebo , OAD , lifestyle intervention or insulin .Outcomes : We included all studies reporting heart rate , blood pressure or body weight outcomes .", "label": "", "metadata": {}, "score": "51.786217"}
{"text": "D. Comparison groups(s ) : placebo , OAD , lifestyle intervention or insulin . E. Outcomes : We included all studies reporting heart rate , blood pressure or body weight outcomes .", "label": "", "metadata": {}, "score": "51.787163"}
{"text": "Nauck MA , Duran S , Kim D , et al .A comparison of twice - daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin : a non - inferiority study .", "label": "", "metadata": {}, "score": "51.820168"}
{"text": "Subjects who completed at least 10 weeks of either treatment period were included in the outcome analysis for that treatment period by using the last - observation - carried - forward method .", "label": "", "metadata": {}, "score": "51.848763"}
{"text": "However , the baseline and end - of - study mean A1C values in the monotherapy group were slightly less than those in the combination therapy group , and the resulting change - from - baseline decreases appeared to be slightly greater in the monotherapy group than in the combination therapy group ( Fig . 1 D ) .", "label": "", "metadata": {}, "score": "51.862762"}
{"text": "Systolic blood pressure decreased by 6.7 , 5.6 , and 1.1 mmHg with 1.2 and 1.8 mg liraglutide and placebo , respectively .Significant increases in C - peptide and homeostasis model assessment of \u03b2 - cell function and significant decreases in the proinsulin - to - insulin ratio occurred with liraglutide versus placebo .", "label": "", "metadata": {}, "score": "51.91302"}
{"text": "Two - hour glucose values trended lower during exenatide treatment compared with placebo , although there was wide variability ( Table 2 ) .There were no significant changes in adiponectin levels , insulin levels , or HOMA of insulin resistance scores when the data were analyzed by responder group ( data not shown ) .", "label": "", "metadata": {}, "score": "51.962517"}
{"text": "3 - 6 Those leading to reduced blood pressure are less adequately understood , but this effect has been shown to occur as early as 2 weeks after the start of the therapy , preceding significant weight loss , suggesting that a direct hypotensive effect is at least partly responsible .", "label": "", "metadata": {}, "score": "51.980095"}
{"text": "In the Diabetes Prevention Study , 50 % of individuals with prediabetes randomized to the intensive lifestyle program were able to lose 7 % of their baseline weight at 6 months .", "label": "", "metadata": {}, "score": "52.001698"}
{"text": "This corresponded to a 2.7 % decrease in body weight during exenatide treatment and a 0.2 % increase in body weight during placebo treatment .A significant decrease in body weight was observed after 2 weeks of exenatide , and the difference persisted for the entire treatment period ( Fig . 1 A ) .", "label": "", "metadata": {}, "score": "52.098976"}
{"text": "Nauck MA , Hompesch M , Filipczak R , Le TD , Zdravkovic M , Gumprecht J : Five weeks of treatment with the GLP-1 analogue liraglutide improves glycemic control and lowers body weight in patients with type 2 diabetes .", "label": "", "metadata": {}, "score": "52.13951"}
{"text": "Apart from the gastrointestinal side effects , liraglutide treatment was generally well tolerated and had a low incidence of hypoglycemia that was comparable to that of the placebo group ( metformin monotherapy ) .", "label": "", "metadata": {}, "score": "52.146706"}
{"text": "et al .Long term effects of exenatide therapy over 82 weeks on glycemic control and weight in overweight metformin treated patients with type 2 diabetes mellitus .", "label": "", "metadata": {}, "score": "52.1652"}
{"text": "The double - dummy design required that subjects in the liraglutide and placebo groups received a glimepiride placebo , whereas subjects in the glimepiride and placebo groups received an injection of liraglutide placebo .", "label": "", "metadata": {}, "score": "52.176136"}
{"text": "It was limited by the significant het- erogeneityofeffectsize individual studies .We examined prespecified subgroups according to the GLP-1 agent and type of comparator measurementsbetween ( placebo or active control ) .", "label": "", "metadata": {}, "score": "52.20963"}
{"text": "Nausea was reported by 11 - 19 % of the liraglutide - treated subjects versus 3 - 4 % in the placebo and glimepiride groups .", "label": "", "metadata": {}, "score": "52.251846"}
{"text": "RESEARCH DESIGN AND METHODS .We conducted a 35-week randomized , double - blind , placebo - controlled , crossover study , with two 16-week treatment periods separated by a 3-week washout period ( Supplementary Fig . 1 ) .", "label": "", "metadata": {}, "score": "52.43126"}
{"text": "[ Time Frame : 48-weeks ] [ Designated as safety issue : No ] .ISSI-2 is a validated OGTT - derived measure of beta - cell function analogous to the disposition index obtained from the intravenous glucose tolerance test .", "label": "", "metadata": {}, "score": "52.54982"}
{"text": "Interaction effects were evaluated using prespecified subgroup analyses ( comparing various doses of the study drug to active control or placebo ) and type of GLP-1 agonist ( liraglutide , exenatide twice daily and exenatide LAR preparations ) .", "label": "", "metadata": {}, "score": "52.586906"}
{"text": "Acknowledgments .The study was funded by the American Diabetes Association ( 7 - 09-NOVO-15 to G.R. ) .Liraglutide and matching placebo were provided by Novo Nordisk .", "label": "", "metadata": {}, "score": "52.589005"}
{"text": "Interim analysis of the effects of exenatide treatment on A1C , weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes .", "label": "", "metadata": {}, "score": "52.611626"}
{"text": "There were no within - group changes in inflammatory markers , with the exception of a decrease in soluble intercellular adhesion molecule and an increase in adiponectin associated with liraglutide treatment .", "label": "", "metadata": {}, "score": "52.757835"}
{"text": "Values are expressed as means \u00b1 SD unless otherwise noted .RESULTS- .A total of 1,662 subjects were screened for the study ; 571 subjects failed the screening criteria or withdrew consent , and the remaining 1,091 subjects were randomly assigned to treatment after the metformin run - in period .", "label": "", "metadata": {}, "score": "52.813923"}
{"text": "In the liraglutide groups , maximal effect on fasting serum glucose was evident after the first week of treatment ( Fig . 1 D ) .", "label": "", "metadata": {}, "score": "52.855865"}
{"text": "Gill A , Hoogwerf BJ , Burger J , et al .Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus : a double blind , placebo controlled , randomized pilot study .", "label": "", "metadata": {}, "score": "52.938957"}
{"text": "Randomization was carried out using a telephone- or Web - based randomization system .Before randomization , eligible subjects underwent a 6- to 9-week metformin and rosiglitazone run - in and dose - titration period .", "label": "", "metadata": {}, "score": "52.941227"}
{"text": "The titration period was followed by a 24-week maintenance period during which the doses of study drugs were to be maintained .The primary outcome measure was change in A1C from randomization to the end of the study .", "label": "", "metadata": {}, "score": "52.977203"}
{"text": "Patients treated with glimepiride had decreased HbA 1c and fasting glucose , but slightly increased body weight .No safety issues were raised for liraglutide ; observed adverse events were mild and transient .", "label": "", "metadata": {}, "score": "53.009125"}
{"text": "Generally , adverse events were mild or moderate and completely resolved .Only 1 of the 135 patients exposed to liraglutide experienced two mild injection site reactions , described as an \" urticarial reaction at injection place .", "label": "", "metadata": {}, "score": "53.016956"}
{"text": "There was no change in body composition using BIA .A : Change in body weight during exenatide and placebo treatment periods .Error bars represent \u00b1 SEM .", "label": "", "metadata": {}, "score": "53.017937"}
{"text": "A total of 24 % of the study population had prediabetes at enrollment .Subjects injected 5 \u03bcg of either exenatide or identically dispensed placebo before breakfast and supper .", "label": "", "metadata": {}, "score": "53.033745"}
{"text": "Peripheral edema was reported by 5.1 , 1.7 , and 8.0 % in the 1.2 mg liraglutide , 1.8 mg liraglutide , and placebo groups , respectively .", "label": "", "metadata": {}, "score": "53.051544"}
{"text": "Page 14 .effect size to a previously reported value for weight loss,2 although our study has distinguished between placebo and active comparators , in which effects sizes differ sub- stantially .", "label": "", "metadata": {}, "score": "53.301723"}
{"text": "Heterogeneity was estimated using the \u03c72test and I2statistic .Fixed and random effects weighted mean difference models using the Inverse Variance tech- nique were used to compare outcomes between the study drug and comparator with 95 % CI .", "label": "", "metadata": {}, "score": "53.39144"}
{"text": "Buse JB , Henry RR , Han J , et al .Effects of exenatide ( exendin-4 ) on glycaemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulphonylurea .", "label": "", "metadata": {}, "score": "53.447865"}
{"text": "53 .Klonoff DC , Buse JB , Nielsen LL , et al .Exenatide effects on diabetes , obesity , cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years .", "label": "", "metadata": {}, "score": "53.449448"}
{"text": "We examined prespecified subgroups according to the GLP-1 agent and type of comparator ( placebo or active control ) .Active control treatments varied between trials and included different classes of OAD and insulins , which may explain some of the variation in measured effect .", "label": "", "metadata": {}, "score": "53.491985"}
{"text": "Buse JB , Drucker DJ , Taylor KL , et al .DURATION-1 : exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks .", "label": "", "metadata": {}, "score": "53.528816"}
{"text": "Bunck MC , Corn\u00e9r A , Eliasson B , et al .Effects of exenatide on measures of beta - cell function after 3 years in metformin - treated patients with type 2 diabetes .", "label": "", "metadata": {}, "score": "53.60327"}
{"text": "Liutkus J , Guzman JR , Norwood P , et al .A placebo - controlled trial of exenatide twice - daily added to thiazolidinediones alone or in combination with metformin .", "label": "", "metadata": {}, "score": "53.745712"}
{"text": "Data on weight loss with exenatide in individuals without diabetes are limited .Astrup et al .( 16 ) showed that 1.2 - 3.0 mg liraglutide daily plus aggressive lifestyle intervention for 20 weeks was associated with dose - dependent , placebo - corrected weight loss , ranging from 2.0 to 4.4 kg among nondiabetic obese individuals .", "label": "", "metadata": {}, "score": "53.79628"}
{"text": "Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea .", "label": "", "metadata": {}, "score": "53.868736"}
{"text": "Another approach for investigating the potential of GLP-1 includes administering native GLP-1 by means of continuous infusion ( 11 , 14 ) .Continuous intravenous infusion of GLP-1 for 1 week resulted in an instant decrease in blood glucose levels in patients in whom sulfonylurea therapy failed to be effective ( 14 ) .", "label": "", "metadata": {}, "score": "53.87579"}
{"text": "Riddle MC , Henry RR , Poon TH , et al .Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin .", "label": "", "metadata": {}, "score": "53.92284"}
{"text": "Zinman B , Hoogerworf BJ , Garcia SD , et al .The effect of adding exenatide to a thiazolidinedione in sub - optimally controlled type 2 diabetes .", "label": "", "metadata": {}, "score": "53.929314"}
{"text": "Proportion of Subjects With HbA1c Below Or Equal to 6.5 % At Week 52 That Are Free From Severe Hypoglycaemic Events [ Time Frame : From week 0 to week 52 after initial transplantation ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "53.95319"}
{"text": "ABSTRACT .Objectives To synthesise current evidence for the effects of exenatide and liraglutide on heart rate , blood pressure and body weight .Design Meta - analysis of available data from randomised controlled trials comparing Glucagon - like peptide-1 ( GLP-1 ) analogues with placebo , active antidiabetic drug therapy or lifestyle intervention .", "label": "", "metadata": {}, "score": "53.954075"}
{"text": "Garber A , Henry R , Ratner R , et al . , for the LEAD-3 ( Mono ) Study Group .Liraglutide versus glimepiride monotherapy for type 2 diabetes ( LEAD-3 Mono ) : a randomised , 52-week , phase III , double - blind , parallel - treatment trial .", "label": "", "metadata": {}, "score": "53.963985"}
{"text": "Barnett AH , Burger J , Johns D , et al .Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 23 . diabetes previously uncontrolled with metformin or a sulphonylurea : a multinational , randomised , open label two period crossover non - inferiority trial .", "label": "", "metadata": {}, "score": "53.985554"}
{"text": "Therefore , tolerance of GLP-1 receptor agonists may vary by population characteristics .In conclusion , this is the first study to evaluate the effect of GLP-1 administration on weight loss , insulin action , and cardiometabolic risk factors in individuals with prediabetes who are older , overweight / obese , and are at high risk for development of T2DM and CVD .", "label": "", "metadata": {}, "score": "54.073067"}
{"text": "Yang W , Chen L , Ji Q , et al .Liraglutide provides similar glycaemic control as glimepiride ( both in combination with metformin ) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China , South Korea and India : a 16-week , randomized , double - blind , active control trial .", "label": "", "metadata": {}, "score": "54.096222"}
{"text": "Liraglutide once - daily human GLP-1 analogue , added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes ( Lead 1-SU ) .", "label": "", "metadata": {}, "score": "54.263657"}
{"text": "Willms B , Werner J , Holst JJ , et al .Gastric emptying , glucose responses , and insulin secretion after a liquid test meal : effects of exogenous glucagon - like peptide-1 ( GLP-1)-(7 - 36 ) amide in type 2 ( noninsulin - dependent ) diabetic patients .", "label": "", "metadata": {}, "score": "54.29873"}
{"text": "Buse JB , Rosenstock J , Sesti G , et al .Liraglutide once a day versus exenatide twice a day for type 2 diabetes : a 26-week randomised , parallel - group , multinational , open label trial ( LEAD-6 ) .", "label": "", "metadata": {}, "score": "54.343742"}
{"text": "No major hypoglycemic events occurred during the randomized treatment period when liraglutide was used as monotherapy or with metformin ( 7 , 9 ) .The current study investigated liraglutide treatment in combination with metformin and a thiazolidinedione ( TZD ) ( rosiglitazone ) as part of the LEAD program .", "label": "", "metadata": {}, "score": "54.3711"}
{"text": "Moretto TJ , Milton DR , Ridge TD . , et al Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug - naive patients with type 2 diabetes : a randomized , double blind , placebo - controlled parallel - group study .", "label": "", "metadata": {}, "score": "54.384476"}
{"text": "Efficacy and safety of exenatide once weekly versus metformin , pioglitazone , and sitagliptin used as monotherapy in drug - na\u00efve patients with type 2 diabetes ( DURATION-4 ) : a 26-week double - blind study .", "label": "", "metadata": {}, "score": "54.613632"}
{"text": "The most relevant position for initiating treatment with GLP-1 may be after metformin failure , but to facilitate recruitment into the trial other monotherapy or combination treatments were allowed .", "label": "", "metadata": {}, "score": "54.81089"}
{"text": "However , in two out of three studies of individuals without diabetes , the drop - out rate was similar to that of the current study , 30 ( 12 ) and 34 % ( 11 ) .", "label": "", "metadata": {}, "score": "54.82168"}
{"text": "Treatment with liraglutide did not increase body weight ( Fig . 2 ) .Furthermore , for the 0.45-mg liraglutide dosage group ( Table 2 ) , a statistically significant decrease , compared with placebo , was observed .", "label": "", "metadata": {}, "score": "54.87168"}
{"text": "This study is designed to examine the efficacy and safety of 2 dose levels of weekly subcutaneously injected albiglutide compared with placebo and an open label reference arm of daily subcutaneous injections of liraglutide , in Japanese subjects with Type 2 diabetes mellitus .", "label": "", "metadata": {}, "score": "54.88633"}
{"text": "Diabet Med 25 : 152 -156 , 2008 .Rolin B , Larsen MO , Gotfredsen CF , Deacon CF , Carr RD , Wilken M , Knudsen LB : The long - acting GLP-1 derivative NN2211 ameliorates glycemia and increases \u03b2 - cell mass in diabetic mice .", "label": "", "metadata": {}, "score": "54.90338"}
{"text": "In combination with metformin , liraglutide reduced body weight by 2 - 3 kg , with the majority of the weight loss being fat ( 11 ) .", "label": "", "metadata": {}, "score": "54.965347"}
{"text": "None of the trials were termi- nated prematurely .Funnel plots were broadly symmet- rical with no evidence of publication bias .Heterogeneity The trials varied in terms of duration of follow - up , loca- tion , type of active comparator drug and background therapy .", "label": "", "metadata": {}, "score": "55.06922"}
{"text": "No safety issues with regard to vital signs , electrocardiogram , or laboratory analysis were raised by this trial .CONCLUSIONS .This trial was the first to demonstrate a sustained improvement in glycemic control after long - term treatment with the GLP-1 analog liraglutide , administered once daily .", "label": "", "metadata": {}, "score": "55.153255"}
{"text": "BMJ Open 2013;3:e001986 .Design : Meta - analysis of available data from randomised controlled trials comparing Glucagon - like peptide-1 ( GLP-1 ) analogues with placebo , active antidiabetic drug therapy or lifestyle intervention .", "label": "", "metadata": {}, "score": "55.349823"}
{"text": "These studies support the effectiveness of this type of diabetes regimen , particularly as it is associated with modest weight loss and low risk of hypoglycemia .", "label": "", "metadata": {}, "score": "55.483994"}
{"text": "Bode BW , Testa MA , Magwire M , et al .Patient - reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy : results from a randomized controlled trial in patients with type 2 diabetes .", "label": "", "metadata": {}, "score": "55.486668"}
{"text": "Liraglutide vs sitagliptin for patients with type 2 diabetes who did not have adequate glycemic control with metformin : a 26 week , randomised , parallel group , open - label trial .", "label": "", "metadata": {}, "score": "55.562866"}
{"text": "The degree of weight loss was comparable with that seen after intensive lifestyle interventions in large clinical trials of prediabetes .In addition , weight loss associated with liraglutide treatment led to significant improvement in insulin resistance , glucose tolerance , and some CVD risk factors .", "label": "", "metadata": {}, "score": "55.622677"}
{"text": "The findings of the current study demonstrate that liraglutide is an effective treatment option for combination therapy with metformin when subjects are not achieving glycemic control with metformin therapy alone .", "label": "", "metadata": {}, "score": "55.661335"}
{"text": "Russell - Jones D , Vaag A , Schmitz O , et al .Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus ( LEAD-5 met+SU ) : a randomised controlled trial .", "label": "", "metadata": {}, "score": "55.7255"}
{"text": "Glycemic control .Glim , glimepiride .Mean weight change from baseline ( kg ) , ITT population .Acknowledgments .This trial was sponsored by Novo Nordisk A / S , which established the protocol in conjunction with an academic committee that was responsible for data review and this article .", "label": "", "metadata": {}, "score": "55.769653"}
{"text": "The increase in pulse has been noted in studies of patients with T2DM treated with liraglutide ( 23 , 24 ) as well as another GLP-1 receptor agonist , exenatide ( 25 ) .", "label": "", "metadata": {}, "score": "55.862823"}
{"text": "The mean glimepiride dosage during the trial was 2.7 mg .Compliance was assessed by drug accountability and plasma concentration measurements .Analytic methods .HbA 1c was analyzed with a Unimate HbA 1c assay ( Roche Diagnostics ; normal range 4.5 - 5.7 % ) .", "label": "", "metadata": {}, "score": "55.900703"}
{"text": "Weight loss , glycemic control , and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database .", "label": "", "metadata": {}, "score": "56.0347"}
{"text": "Most of these adverse event withdrawals caused by gastrointestinal disorders occurred during the first month of therapy .One subject in the 1.2 mg liraglutide group and one in the glimepiride group were withdrawn for acute pancreatitis during the study .", "label": "", "metadata": {}, "score": "56.03766"}
{"text": "DeFronzo RA , Ratner RE , Han J , et al .Effects of exenatide ( exendin-4 ) on glycemic control and weight over 30 weeks in metformin - treated patients with type 2 diabetes .", "label": "", "metadata": {}, "score": "56.124504"}
{"text": "In rats , both peripheral and central administration of GLP-1 receptor agonists increased blood pressure and heart rate by activating autonomic regulatory sites in the rat brain ( 22 ) .", "label": "", "metadata": {}, "score": "56.276123"}
{"text": "Drucker D , Buse JB , Taylor K , et al .Exenatide once - weekly versus twice daily for the treatment of type 2 diabetes : a randomized open - label , non - inferiority study .", "label": "", "metadata": {}, "score": "56.397728"}
{"text": "Kadowaki T , Namba M , Yamamura A , et al .Exenatide exhibits dose - dependent effects on glycemic control over 12 weeks in Japanese patients with suboptimally controlled type 2 diabetes .", "label": "", "metadata": {}, "score": "56.420364"}
{"text": "A comparison of twice - daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin : a non - inferiority study .", "label": "", "metadata": {}, "score": "56.424946"}
{"text": "In nine trials , at least one arm was open label .Attrition was adequately described and was greater than 20 % in nine studies .", "label": "", "metadata": {}, "score": "56.441822"}
{"text": "Objectives To synthesise current evidence for the effects of exenatide and liraglutide on heart rate , blood pressure and body weight .Design Meta - analysis of available data from randomised controlled trials comparing Glucagon - like peptide-1 ( GLP-1 ) analogues with placebo , active antidiabetic drug therapy or lifestyle intervention .", "label": "", "metadata": {}, "score": "56.63006"}
{"text": "Diabetes Care 2009 ; 32 : 762 - 8 . . .Liraglutide , a long - acting human glucagon - like peptide-1 analog , given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes .", "label": "", "metadata": {}, "score": "56.700478"}
{"text": "et al .Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug - naive patients with type 2 diabetes : a randomized , double blind , placebo - controlled parallel - group study .", "label": "", "metadata": {}, "score": "56.705135"}
{"text": "Abstract .OBJECTIVE To determine the efficacy and safety of liraglutide ( a glucagon - like peptide-1 receptor agonist ) when added to metformin and rosiglitazone in type 2 diabetes .", "label": "", "metadata": {}, "score": "56.73169"}
{"text": "Bunck MC , Diamant M , Corner A , et al .One - year treatment with exenatide improves beta - cell function , compared with insulin glargine , in metformin - treated type 2 diabetic patients : a randomized , controlled trial .", "label": "", "metadata": {}, "score": "56.794876"}
{"text": "Buse JB , Henry RR , Han J , Kim DD , Fineman MS , Baron AD : Effects of exenatide ( exendin-4 ) on glycemic control over 30 weeks in sulfonylurea - treated patients with type 2 diabetes .", "label": "", "metadata": {}, "score": "56.844215"}
{"text": "Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulphonylurea : a multinational , randomised , open label two period crossover non - inferiority trial .", "label": "", "metadata": {}, "score": "56.85456"}
{"text": "The open - label liraglutide group was a reference group ; descriptive statistics comparing albiglutide and liraglutide were exploratory endpoints .Change From Baseline in HbA1c at Week 52 [ Time Frame : Baseline and Week 52 ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "56.903328"}
{"text": "Gallwitz B , Guzman J , Dotta F , et al .Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure ( EUREXA ) : an open - label , randomised controlled trial .", "label": "", "metadata": {}, "score": "56.93685"}
{"text": ": the LEAD-2 Study Group .Efficacy and safety comparison of liraglutide , glimepiride , and placebo , all in combination with metformin , in type 2 diabetes : the LEAD ( liraglutide effect and action in diabetes)-2 study .", "label": "", "metadata": {}, "score": "57.00155"}
{"text": "For most outcomes , we found significant heterogeneity ( figures 2 - 6 ) .We , therefore , chose to report results using the random effects approach , although the differ- ences between random effects and fixed effect results werevery small .", "label": "", "metadata": {}, "score": "57.033592"}
{"text": "For most GLP-1 trials , heart rate is a secondary outcome measured as part of safety assessment , and is reported inconsistently .In clinic , it is often measured using a very short sampling interval ( perhaps 1 min of data ) .", "label": "", "metadata": {}, "score": "57.062996"}
{"text": "For most GLP-1 trials , heart rate is a secondary outcome measured as part of safety assessment , and is reported inconsistently .In clinic , it is often measured using a very short sampling interval ( perhaps 1 min of data ) .", "label": "", "metadata": {}, "score": "57.062996"}
{"text": "Toft - Nielsen MB , Madsbad S , Holst JJ : Continuous subcutaneous infusion of glucagon - like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients .", "label": "", "metadata": {}, "score": "57.075417"}
{"text": "Zander M , Madsbad S , Madsen JL , Holst JJ : Effect of 6-week course of glucagon - like peptide 1 on glycaemic control , insulin sensitivity , and beta - cell function in type 2 diabetes : a parallel - group study .", "label": "", "metadata": {}, "score": "57.1446"}
{"text": "Adjusted end point levels at 12-week follow - up were calculated for each treatment group by means of this model .All analyses were performed for the intention - to - treat ( ITT ) population ( i.e. , all patients who received at least one dose of a trial drug ) .", "label": "", "metadata": {}, "score": "57.181904"}
{"text": "We excluded ' open - label ' extension studies of phase 3 trials .Interventions : Trials of liraglutide ( 1.2 or 1.8 mg daily ) , exenatide ( 5 or 10 \u00b5g twice daily ) or exenatide LAR , either alone or in combination with an oral anti - diabetic drug ( OAD ) or insulin , were included .", "label": "", "metadata": {}, "score": "57.29815"}
{"text": "Subjects were encouraged to inject liraglutide at the same time each day .The titration period was followed by a 23- or 24-week maintenance period during which the doses of study drugs were to be maintained .", "label": "", "metadata": {}, "score": "57.361702"}
{"text": "Descriptive summary statistics are provided as a separate outcome measure .Mean HbA1c at Baseline , Week 24 , and Change From Baseline at Week 24 [ Time Frame : Baseline and Week 24 ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "57.366302"}
{"text": "Lancet 2012 ; 379 : 2243 - 2251 pmid : 22683134 .Liraglutide , a once - daily human GLP-1 analogue , added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes ( LEAD-1 SU ) .", "label": "", "metadata": {}, "score": "57.37258"}
{"text": "Participants who discontinued the study before Week 24 had their last post - Baseline HbA1c value carried forwrad for the summary unless the value was past 14 days after the last dose of study drug .", "label": "", "metadata": {}, "score": "57.378418"}
{"text": "Missing data were imputed as the last observation carried forward .Sample size calculations were based on showing A1C and body weight differences of 0.5 and 3 % , respectively , after 6 months of treatment .", "label": "", "metadata": {}, "score": "57.385956"}
{"text": "Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes ( DURATION-2 ) : a randomised trial .", "label": "", "metadata": {}, "score": "57.44678"}
{"text": "The five dosages of liraglutide administered were 0.045 , 0.225 , 0.45 , 0.60 , and 0.75 mg .These dosages were chosen based on observations from previous trials ( 16 - 18 ) .", "label": "", "metadata": {}, "score": "57.515873"}
{"text": "No preview \u00b7 Article \u00b7 Oct 2014 \u00b7 Therapeutic advances in endocrinology and metabolism .\" The average weight loss amounted to 1.6 kg in the exenatide - treated groups .", "label": "", "metadata": {}, "score": "57.544643"}
{"text": "J Clin Endocrinol Metab 87 : 1239 -1246 , 2002 .Ritzel R , Orskov C , Holst JJ , Nauck MA : Pharmacokinetic , insulinotropic , and glucagonostatic properties of GLP-1 [ 7 - 36 amide ] after subcutaneous injection in healthy volunteers : dose - response - relationships .", "label": "", "metadata": {}, "score": "57.58723"}
{"text": "Liraglutide once a day versus exenatide twice a day for type 2 diabetes : a 26-week randomized , parallel - group , multinational , open - label trial ( LEAD-6 ) .", "label": "", "metadata": {}, "score": "57.612183"}
{"text": "Both deaths were unrelated to liraglutide treatment .No major hypoglycemic events were reported .No clinically relevant between - treatment differences were observed in physical examination findings , laboratory analyses ( hematology and biochemistry analyses ) , electrocardiogram , or ophthalmoscopy .", "label": "", "metadata": {}, "score": "57.666416"}
{"text": "Participants who discontinued from study treatment before Week 24 had their last post - Baseline HbA1c carried forward for the analysis unless the value is past 14 days after the last dose of study drug .", "label": "", "metadata": {}, "score": "57.716812"}
{"text": "Kendall DM , Riddle MC , Rosenstock J , et al .Effects of exenatide ( Exendin-4 ) on glycaemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulphonylurea .", "label": "", "metadata": {}, "score": "57.755272"}
{"text": "A large nationwide audit of exenatide designed by the Association of British Clinical Diabetologists ( ABCD ) did not include heart rate as an outcome , despite citing evidence for the effect in the main published report .", "label": "", "metadata": {}, "score": "57.760834"}
{"text": "RESEARCH DESIGN AND METHODS .Subjects .Men and women , aged 40 - 70 years , with BMI of 27 - 40 kg / m 2 with prediabetes were recruited from a single center from December 2009 to December 2012 .", "label": "", "metadata": {}, "score": "57.8332"}
{"text": "The Baseline HbA1c value is defined as the last nonmissing value before the start of treatment .Change from Baseline was calculated as the value at Week 24 minus the value at Baseline .", "label": "", "metadata": {}, "score": "57.899017"}
{"text": "Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus ( LEAD-5 met+SU ) : a randomised controlled trial .", "label": "", "metadata": {}, "score": "57.91829"}
{"text": "For the effect of liraglutide on heart rate compared with placebo , the I2value was 55 % .varied significantly Figure 5 GLP-1 agonists ' effect on diastolic blood pressure in patients with type 2 diabetes .", "label": "", "metadata": {}, "score": "57.94193"}
{"text": "Marre M , Shaw J , Brandle M , et al .Liraglutide once - daily human GLP-1 analogue , added to a sulphonylurea over 26 weeks produces 44 .", "label": "", "metadata": {}, "score": "57.95087"}
{"text": "Subjects will be randomly assigned to double blind matching albiglutide placebo administered weekly .Subjects will then cross - over to double - blind treatment with albiglutide 30 mg weekly at Week 24 until Week 52 .", "label": "", "metadata": {}, "score": "57.956844"}
{"text": "Vilsboll T , Krarup T , Deacon CF , Madsbad S , Holst JJ : Reduced postprandial concentrations of intact biologically active glucagon - like peptide 1 in type 2 diabetic patients .", "label": "", "metadata": {}, "score": "58.23606"}
{"text": "Feinglos MN , Saad MF , Pi - Sunyer FX , et al .Effects of liraglutide ( NN2211 ) , a long - acting GLP-1 analogue , on glycaemic control and bodyweight in subjects with Type 2 diabetes .", "label": "", "metadata": {}, "score": "58.291996"}
{"text": "Brief Summary .This trial is conducted in Europe and North America .The aim of this trial is to investigate if liraglutide treatment can increase the proportion of insulin - independent subjects one year after islet cell transplantation who required only one ( single - donor ) islet cell transplant .", "label": "", "metadata": {}, "score": "58.328392"}
{"text": "Satiety and hunger scores were not significantly different during exenatide and placebo treatment .Three subjects with ongoing nausea or abdominal pain had lipase levels measured .", "label": "", "metadata": {}, "score": "58.507248"}
{"text": "( 11 ) after administration of exenatide to obese subjects without diabetes .Although subjects in their study experienced significantly greater weight loss with exenatide , there was no difference in blood pressure or lipid concentrations compared with placebo .", "label": "", "metadata": {}, "score": "58.589237"}
{"text": "Prediabetes was defined as having elevated fasting glucose ( 5.6 - 6.9 mmol / L ) or elevated 2-h glucose ( 7.8 - 11.0 mmol / L ) concentration after a 75-g oral glucose challenge .", "label": "", "metadata": {}, "score": "58.61451"}
{"text": "Gastrointestinal disorders ( including nausea , vomiting , and diarrhea ) were the most frequently reported adverse events in the liraglutide groups and were reported by 45 , 56 , and 19 % of the subjects in the 1.2 and 1.8 mg liraglutide and placebo groups , respectively .", "label": "", "metadata": {}, "score": "58.633614"}
{"text": "The primary outcome measure was change in A1C at the end of the study .Laboratory analyses were performed by a central laboratory ( MDS Pharma Services in Canada , France , Germany , Singapore , and Switzerland and Laboratories Hildago in Argentina ) .", "label": "", "metadata": {}, "score": "58.68999"}
{"text": "Proportion of Insulin - Independent Subjects [ Time Frame : At 52 weeks after initial transplantation ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "58.730824"}
{"text": "Finally , none of the previous studies of nondiabetic populations has measured peripheral insulin action quantified by a specific technique .Two of these studies used a surrogate estimate of insulin action , the homeostasis model assessment of insulin resistance ( HOMA - IR ) ( 10 , 12 ) .", "label": "", "metadata": {}, "score": "58.737198"}
{"text": "Wysham C , Bergenstal R , Malloy J , et al .DURATION-2 : efficacy and safetyof switching from maximum daily sitagliptin or pioglitazone to once - weekly exenatide .", "label": "", "metadata": {}, "score": "59.03827"}
{"text": "Nauck MA , Kleine N , Orskov C , Holst JJ , Willms B , Creutzfeldt W : Normalization of fasting hyperglycaemia by exogenous glucagon - like peptide 1 ( 7 - 36 amide ) in type 2 ( non - insulin - dependent ) diabetic patients .", "label": "", "metadata": {}, "score": "59.18022"}
{"text": "Robinson LE , Holt TA , Rees K , et al .BMJ Open 2013;3:e001986 .Page 12 .However , this value reduced to 0 % when the data from a single trial ( LEAD-1 ) were withheld .", "label": "", "metadata": {}, "score": "59.20646"}
{"text": "Gallwitz B , Bohmer M , Segiet T , et al .Exenatide twice daily versus premixed insulin aspart 70/30 in metformin - treated patients with type 2 diabetes : a randomized 26-week study on glycemic control and hypoglycaemia .", "label": "", "metadata": {}, "score": "59.245293"}
{"text": "Defronzo RA , Triplitt C , Qu Y , et al .Effects of exenatide plus rosiglitazone on beta - cell function and insulin sensitivity in subjects with type 2 diabetes on metformin .", "label": "", "metadata": {}, "score": "59.273617"}
{"text": "J Clin Endocrinol Metab 81 : 327 -332 , 1996 .Gutniak M , Orskov C , Holst JJ , Ahren B , Efendic S : Antidiabetogenic effect of glucagon - like peptide-1 ( 7 - 36)amide in normal subjects and patients with diabetes mellitus .", "label": "", "metadata": {}, "score": "59.28479"}
{"text": "However , the small rise in heart rate is a reason for caution , as it might potentially be associated with adverse outcomes .This rise was more evident for liraglutide than exenatide twice daily , but exenatide LAR may produce a greater response than the twice - daily formulation .", "label": "", "metadata": {}, "score": "59.333733"}
{"text": "However , the small rise in heart rate is a reason for caution , as it might potentially be associated with adverse outcomes .This rise was more evident for liraglutide than exenatide twice daily , but exenatide LAR may produce a greater response than the twice - daily formulation .", "label": "", "metadata": {}, "score": "59.333733"}
{"text": "A subset of individuals demonstrated robust weight loss that was detected very early in the course of treatment .The recent withdrawal of sibutramine from the market leaves only two Food and Drug Administration - approved pharmacologic agents for the treatment of obesity , phentermine and orlistat ( 1 ) .", "label": "", "metadata": {}, "score": "59.33918"}
{"text": "The majority of nausea was transient , as it occurred in the first 4 weeks of liraglutide treatment ( 216 events in weeks 1 - 4 vs. 65 events in weeks 4 - 26 ) ( Fig .", "label": "", "metadata": {}, "score": "59.380764"}
{"text": "Nausea , vomiting , and/or diarrhea were the gastrointestinal events that lead to the withdrawal of five subjects treated with 1.2 mg liraglutide and 19 subjects treated with 1.8 mg liraglutide ( Table 1 ) .", "label": "", "metadata": {}, "score": "59.382065"}
{"text": "The results of our study demonstrated that addition of liraglutide to a calorie - restricted diet can significantly augment weight loss compared with placebo in individuals at high risk for T2DM and CVD .", "label": "", "metadata": {}, "score": "59.414154"}
{"text": "Higher attrition in the exenatide arm 19 20 21 22 23 Higher attrition in the placebo arm .\u00a7 Randomised according to the baseline biochemical values or background pharmacological agent .", "label": "", "metadata": {}, "score": "59.52976"}
{"text": "Bunck MC , Corn\u00e9r A , Eliasson B , et al .One year treatment with exenatide vs. insulin glargine : effects on post - prandial glycemia , lipid profiles and oxidative stress .", "label": "", "metadata": {}, "score": "59.61392"}
{"text": "Fineman MS , Bicsak TA , Shen LZ , Taylor K , Gaines E , Varns A , Kim D , Baron AD : Effect on glycemic control of exenatide ( synthetic exendin-4 ) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes .", "label": "", "metadata": {}, "score": "59.696415"}
{"text": "Juhl CB , Hollingdal M , Sturis J , Jakobsen G , Agerso H , Veldhuis J , Porksen N , Schmitz O : Bedtime administration of NN2211 , a long - acting GLP-1 analog , substantially reduces fasting and postprandial glycemia in type 2 diabetes .", "label": "", "metadata": {}, "score": "59.711357"}
{"text": "Our cohort of women lost , on average , 2.5 kg after 16 weeks of exenatide treatment , and we observed significant weight loss after only 2 weeks .", "label": "", "metadata": {}, "score": "59.74317"}
{"text": "There were no statistically significant differences between the liraglutide groups and the placebo group for fasting insulin , C - peptide , and glucagon ( Table 2 ) .", "label": "", "metadata": {}, "score": "59.848507"}
{"text": "19 A review of trial data from five long - acting GLP-1 agonists ( exenatide once weekly , taspoglutide , albiglutide , LY2189265 and CJC-1134-PC ) concluded that they were more likely than shorter acting formulations to raise the heart rate .", "label": "", "metadata": {}, "score": "59.8692"}
{"text": "Liraglutide versus glimepiride monotherapy for type 2 diabetes ( LEAD-3 Mono ) : a randomised , 52-week , phase III , double - blind , parallel - treatment trial .", "label": "", "metadata": {}, "score": "59.88129"}
{"text": "For general information , see Learn About Clinical Studies .Please refer to this study by its ClinicalTrials.gov identifier : NCT01270789 Abstract .OBJECTIVE -The efficacy and safety of adding liraglutide ( a glucagon - like peptide-1 receptor agonist ) to metformin were compared with addition of placebo or glimepiride to metformin in subjects previously treated with oral antidiabetes ( OAD ) therapy .", "label": "", "metadata": {}, "score": "59.919834"}
{"text": "Nausea visual analog scale scores increased during the exenatide treatment period compared with placebo .Scores were highest at week 4 and then decreased over the remainder of the treatment period .", "label": "", "metadata": {}, "score": "59.948917"}
{"text": "Another effect of liraglutide that is independent of weight loss is the increase in heart rate .This change also was reported by Astrup et al .", "label": "", "metadata": {}, "score": "59.991096"}
{"text": "These results suggest that TRT could improve clinical and metabolic parameters in obese , type 2 diabetic men with ED and overt hypogonadism ( independently of when T deficit occurred ) .", "label": "", "metadata": {}, "score": "60.06057"}
{"text": "The glucose - lowering effects of the two doses of liraglutide were similar , although there were significantly more gastrointestinal adverse events with the higher dose .", "label": "", "metadata": {}, "score": "60.078297"}
{"text": "Subjects wore a watch - sized sleep monitor and an accelerometer ( Actigraph and Actical ; Mini Mitter ) on the nondominant wrist for 2 weeks during each treatment period .", "label": "", "metadata": {}, "score": "60.081112"}
{"text": "Ann Intern Med 2007;146:477 - 85 .Zinman B , Gerich J , Buse J , et al .Efficacy and safety of the human glucagon - like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes ( LEAD-4 Met+TZD ) .", "label": "", "metadata": {}, "score": "60.09253"}
{"text": "Kendall DM , Riddle MC , Rosenstock J , Zhuang D , Kim DD , Fineman MS , Baron AD : Effects of exenatide ( exendin-4 ) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea .", "label": "", "metadata": {}, "score": "60.099407"}
{"text": "There were no episodes of pancreatitis , and no deaths occurred .Serious adverse events were infrequent ( 8 subjects [ 8 total events ] for 1.2 mg liraglutide , 7 subjects [ 10 events ] for 1.8 mg liraglutide , and 12 subjects [ 13 events ] for placebo ) .", "label": "", "metadata": {}, "score": "60.209396"}
{"text": "DeFronzo RA , Ratner RE , Han J , Kim DD , Baron AD : Effects of exenatide ( exendin-4 ) on glycemic control and weight over 30 weeks in metformin - treated patients with type 2 diabetes .", "label": "", "metadata": {}, "score": "60.236443"}
{"text": "Gao Y , Yoon KH , Chuang L - M , et al .Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylurea .", "label": "", "metadata": {}, "score": "60.327023"}
{"text": "( 10 ) described the impact of treatment with several doses of liraglutide compared with placebo and orlistat in obese individuals without diabetes .Although all doses of liraglutide significantly increased weight loss compared with placebo , improvements in CVD risk factors were less pronounced than those observed in our study , with no significant improvement in lipid concentrations between those randomized to liraglutide and placebo .", "label": "", "metadata": {}, "score": "60.327915"}
{"text": "Buse JB , Bergenstal RM , Glass LC , et al .Use of twice daily exenatide in basal insulin - treated patients with type 2 diabetes .", "label": "", "metadata": {}, "score": "60.335228"}
{"text": "For insulin resistance , no differences were seen among the three treatments ( liraglutide , glimepiride , and placebo ; data not shown ) .Further , the proinsulin - to - insulin ratio decrease was statistically significantly after treatment with 0.75 mg liraglutide compared with placebo ( Table 2 ) .", "label": "", "metadata": {}, "score": "60.471558"}
{"text": "Approximately one - third of adults in the United States have prediabetes ( 1 , 2 ) and are at risk for type 2 diabetes ( T2DM ) and cardiovascular disease ( CVD ) ( 3 ) .", "label": "", "metadata": {}, "score": "60.479275"}
{"text": "Rosiglitazone was started at 4 mg in the morning and increased to 8 mg / day ( 4 mg in the morning and evening , the highest approved dose in the U.S. and Canada ) .", "label": "", "metadata": {}, "score": "60.60812"}
{"text": "Early studies of human GLP-1 showed that continuous peripheral infusion was associated with decreased appetite and increased satiety ( 9 ) .Continuous infusion of GLP-1 also was shown to improve insulin sensitivity , glycemic control , and \u03b2 - cell function in individuals with type 2 diabetes ( 10 ) .", "label": "", "metadata": {}, "score": "60.663017"}
{"text": "Blevins T , Pullman J , Malloy J , et al .DURATION 5 : exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes .", "label": "", "metadata": {}, "score": "60.669754"}
{"text": "In the Diabetes Prevention Program study , a weight loss goal of 7 % was associated with a significant reduction in T2DM incidence ( 4 ) .", "label": "", "metadata": {}, "score": "60.778854"}
{"text": "Ann Int Med 2011;154:103 - 12 .Davies MJ , Donnelly R , Barnett AH , et al .Exenatide compared with long - acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes : results of helping evaluate exenatide in patients with diabetes compared with long - acting insulin ( HEELA ) study .", "label": "", "metadata": {}, "score": "60.819862"}
{"text": "We report the estimated mean or \u0394 along with the P value and 95 % CIs .For repeated measures , we used linear mixed models to compare treatment differences over time .", "label": "", "metadata": {}, "score": "60.87482"}
{"text": "The Baseline FPG value is defined as the last non - missing value before the start of treatment .Change from Baseline was calculated as the FPG value at Week 24 minus the FPG value at Baseline .", "label": "", "metadata": {}, "score": "60.891747"}
{"text": "Current treatment with oral antidiabetic medication was discontinued at screening .Patients were supplied with a blood glucose meter ( One Touch Profile Glucometer ) and instructed in its use .", "label": "", "metadata": {}, "score": "60.953426"}
{"text": "In addition , these previous studies differed substantially from ours in the experimental population and results .This difference in experimental phenotype may help explain why the improvement in cardiometabolic risk factors was more pronounced in the current study .", "label": "", "metadata": {}, "score": "61.04058"}
{"text": "Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylurea .Diabetes Res Clin Pract 2009 ; 83 : 69 - 76 . . .", "label": "", "metadata": {}, "score": "61.04468"}
{"text": "Outcome measures Weighted mean differences between trial arms for changes in heart rate , blood pressure and body weight , after a minimum of 12-week follow - up .", "label": "", "metadata": {}, "score": "61.291737"}
{"text": "Outcome measures Weighted mean differences between trial arms for changes in heart rate , blood pressure and body weight , after a minimum of 12-week follow - up .", "label": "", "metadata": {}, "score": "61.291737"}
{"text": "Subjects were randomly assigned to the lowest available randomization number and stratified with respect to their previous use of OAD monotherapy or combination therapy .Subjects completing the study could enroll in an 18-month open - label extension period .", "label": "", "metadata": {}, "score": "61.295433"}
{"text": "Analyses were stratified by active control or placebo .We compared heterogeneity measures between these subgroups and according to the GLP-1 agent .We also undertook sensitivity analyses to investigate the influence of trial designs on heterogeneity measures , including the background OAD treatment common to both arms .", "label": "", "metadata": {}, "score": "61.33358"}
{"text": "Our study was powered for the primary outcome of weight loss during exenatide versus placebo treatment .A larger , prospective study will be required to examine the metabolic parameters that may predict the degree of response to exenatide treatment .", "label": "", "metadata": {}, "score": "61.39114"}
{"text": "In contrast to the weight - increasing effects of several traditional antidiabetic drug classes , 1 Glucagon - like peptide-1 ( GLP-1 ) analogues have been shown to reduce both body weight and blood pressure .", "label": "", "metadata": {}, "score": "61.41841"}
{"text": "The variable response to exenatide was apparent as early as 4 weeks .To our knowledge , this is the first study to report stratified weight loss in response to exenatide treatment in obese , nondiabetic individuals .", "label": "", "metadata": {}, "score": "61.443153"}
{"text": "Diabetes 2008 ; 57 ( Suppl . 1 ): A32 Current Secondary Outcome Measures ICMJE ( submitted : June 2 , 2014 ) .Number of Hypoglycaemic Episodes [ Time Frame : During week 0 to week 52 ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "61.491257"}
{"text": "BMJ Open 2013;3:e001986 .Page 13 .DISCUSSION We have confirmed and quantified the effects of liragu- tide and exenatide on heart rate , blood pressure and body weight .", "label": "", "metadata": {}, "score": "61.530315"}
{"text": "Change From Baseline in Fasting Plasma Glucose ( FPG ) at Week 24 [ Time Frame : Baseline and Week 24 ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "61.726227"}
{"text": "Outcome measures : Weighted mean differences between trial arms for changes in heart rate , blood pressure and body weight , after a minimum of 12-week follow - up .", "label": "", "metadata": {}, "score": "61.74913"}
{"text": "Vilsboll T , Zdravkovic M , Le - Thi T , et al .Liraglutide , a long - acting human glucagon - like peptide-1 analog , given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes .", "label": "", "metadata": {}, "score": "61.78405"}
{"text": "J Clin Endocrinol Metab 2008 ; 93 : 2670 - 2678 pmid : 18460557 .Measurement of insulin - mediated glucose uptake : Direct comparison of the modified insulin suppression test and the euglycemic , hyperinsulinemic clamp .", "label": "", "metadata": {}, "score": "61.82751"}
{"text": "Our study included a small cohort of generally healthy obese women , which limits the generalizability of our findings .The overall drop - out rate was 35 % , with 17 % dropping out prior to being randomly assigned and 18 % dropping out after being randomly assigned .", "label": "", "metadata": {}, "score": "61.828053"}
{"text": "Therefore , to avoid causing unacceptable side effects , the highest dosage included in this trial was 0.75 mg , corresponding to 7.5 \u03bcg / kg ( equivalent to 10.5 \u03bcg / kg in steady state ) for a person weighing 100 kg .", "label": "", "metadata": {}, "score": "61.85615"}
{"text": "All blood samples were collected after 12 h of fasting .Oral glucose tolerance test .A standard 75-g oral glucose tolerance test was performed at screening to confirm diagnosis of prediabetes and to exclude individuals with normal glucose tolerance or diabetes .", "label": "", "metadata": {}, "score": "61.927284"}
{"text": "Goldberg RB , Holvey SM , Schneider J : A dose - response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents : the Glimepiride Protocol # 201 Study Group .", "label": "", "metadata": {}, "score": "62.140556"}
{"text": "Not Provided .Original Other Outcome Measures ICMJE .Not Provided .Descriptive Information .Brief Title ICMJE .Efficacy and Safety of Liraglutide in Subjects With Type 1 Diabetes Undergoing Islet Cell Transplantation .", "label": "", "metadata": {}, "score": "62.18403"}
{"text": "Heine RJ , Van Gaal LF , Johns D , et al . , GWAA Study Group .Exenatide vs insulin glargine in patients with suboptimally controlled type 2 diabetes : a randomised trial .", "label": "", "metadata": {}, "score": "62.20604"}
{"text": "Efficacy and safety of the human glucagon - like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes ( LEAD-4 Met+TZD ) .", "label": "", "metadata": {}, "score": "62.32675"}
{"text": "Efficacy and safety of the human glucagon - like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes ( LEAD-4 Met+TZD ) .", "label": "", "metadata": {}, "score": "62.32678"}
{"text": "The resultant plasma half - life of liraglutide is substantially prolonged to 13 h compared with the very short half - life of native human GLP-1 ( 6 , 7 ) .", "label": "", "metadata": {}, "score": "62.353416"}
{"text": "RESULTS .Enrollment .The 193 patients randomized in this trial were evenly distributed across treatment groups ( Table 1 ) .Baseline clinical characteristics of the 190 patients exposed to the experimental protocol are given in Table 1 .", "label": "", "metadata": {}, "score": "62.684544"}
{"text": "RESEARCH DESIGN AND METHODS .Subjects who used insulin during the previous 3 months ( except short - term treatment ) were excluded .The protocol was approved by local institutional review boards , and subjects provided written informed consent before the initiation of any trial - related activities .", "label": "", "metadata": {}, "score": "62.84153"}
{"text": "Differences in baseline characteristics between the two randomized groups of the study were assessed with t tests .Baseline demographic data for all study participants are presented as the mean \u00b1 SD .", "label": "", "metadata": {}, "score": "62.84703"}
{"text": "HbA 1c , fasting serum glucose , insulin , C - peptide , and glucagon were measured every 4 weeks .Fasting serum glucose was also measured after the first week of treatment .", "label": "", "metadata": {}, "score": "62.854286"}
{"text": "Study visits occurred every 2 weeks .Primary outcome .The primary outcomes of body weight ( kg ) and BMI ( kg / m 2 ) were measured at all study visits , with subjects wearing light clothing and no shoes .", "label": "", "metadata": {}, "score": "62.882977"}
{"text": "A recent review of liraglutide by Bode acknowledges the effect , 14 but a meta - analysis on the safety of incretin - based therapies published in 2010 did not mention heart rate , 15 and neither did an overview of the LEAD trials of liraglutide by Blonde and Russell - Jones .", "label": "", "metadata": {}, "score": "62.932076"}
{"text": "Targeted sample size of 30 subjects in each group provided 90 % power to detect a 20 % difference ( 2.2 mmol / L ) in SSPG concentration .", "label": "", "metadata": {}, "score": "62.93659"}
{"text": "Weight loss ranging from 2 to 6 kg has been a consistent finding in studies designed to investigate the glycemic benefits of incretin mimetics in individuals with type 2 diabetes ( 11 - 14 ) .", "label": "", "metadata": {}, "score": "63.091743"}
{"text": "Naslund E , Gutniak M , Skogar S , Rossner S , Hellstrom PM : Glucagon - like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men .", "label": "", "metadata": {}, "score": "63.102127"}
{"text": "Lancet 1998 ; 352 : 837 - 53 .: the LEAD-3 ( Mono ) Study Group .Liraglutide versus glimepiride monotherapy for type 2 diabetes ( LEAD-3 Mono ) : a randomised , 52-week , phase III , double - blind , parallel - treatment trial .", "label": "", "metadata": {}, "score": "63.10408"}
{"text": "This is also known as the \" overworked \u03b2 - cell \" hypothesis ( 26 ) .An alternative hypothesis is that the increased proinsulin concentration is related to an intrinsic \u03b2 - cell defect in type 2 diabetes ( 24 ) .", "label": "", "metadata": {}, "score": "63.143585"}
{"text": "After 2 years , the percentage of maintained weight loss diminishes even more ( 6 ) .In contrast , bariatric surgery is the most successful intervention for achieving long - term weight loss in morbid obesity ( 7 ) .", "label": "", "metadata": {}, "score": "63.194496"}
{"text": "Error bars in A , B , C , and D represent 2 \u00d7 SEM .Percentages of subjects achieving ADA ( E ) and AACE ( F ) A1C goals at the end of the study were determined using a logistic regression analysis .", "label": "", "metadata": {}, "score": "63.23554"}
{"text": "Discussion .We have confirmed and quantified the effects of liragutide and exenatide on heart rate , blood pressure and body weight .Our analysis benefited from the inclusion of unpublished data supplied by Novo Nordisk and Amylin Pharmaceuticals , as these were often missing from published trial reports .", "label": "", "metadata": {}, "score": "63.24038"}
{"text": "Conclusions : GLP-1 analogues are associated with a small increase in heart rate and modest reductions in body weight and blood pressure .Mechanisms underlying the rise in heart rate require further investigation .", "label": "", "metadata": {}, "score": "63.258873"}
{"text": "The incidence of gastrointestinal effects in this study increased dose dependently during the first 2 weeks of liraglutide treatment but decreased thereafter .In studies with treatment of exenatide , subjects reported nausea that also decreased in incidence over time ( 16 , 18 , 19 ) .", "label": "", "metadata": {}, "score": "63.291504"}
{"text": "To evaluate the effects of exenatide treatment in obese , nondiabetic women , we designed a randomized , placebo - controlled , crossover study .To minimize the placebo effect and study the effect of exenatide in a real - world setting , we did not include any lifestyle modifications , and we discouraged any change in diet or physical activity .", "label": "", "metadata": {}, "score": "63.32506"}
{"text": "Key messages .Our analysis confirms the weight and blood pressure reducing effects of liraglutide and exenatide , and reports a small rise in heart rate .", "label": "", "metadata": {}, "score": "63.416634"}
{"text": "Effects of moderate variations in macronutrient composition on weight loss and reduction in cardiovascular disease risk in obese , insulin - resistant adults .Am J Clin Nutr 2006 ; 84 : 813 - 821 pmid : 17023708 .", "label": "", "metadata": {}, "score": "63.48812"}
{"text": "Bode B. An overview of the pharmacokinetics , efficacy and safety of liraglutide .Diab Res Clin Pract 2012;97:27 - 42 .Fakhoury WKH , Lereun C , Wright D. A meta - analysis of placebo - controlled clinical trials assessing the efficacy and safety of incretin - based medications in patients with type 2 diabetes .", "label": "", "metadata": {}, "score": "63.591187"}
{"text": "6 Robinson LE , Holt TA , Rees K , et al .BMJ Open 2013;3:e001986 .Page 7 . B. Study designs : We included all randomised trials with a minimum follow - up of 12 weeks .", "label": "", "metadata": {}, "score": "63.605537"}
{"text": "Table 1 Continued Study Pratley et al68 Russell - Jones et al69 Russell - Jones et al70 Comparisons Duration ( weeks )Study population/ ethnicityCountry Body weight groups included Balanced male / female ?", "label": "", "metadata": {}, "score": "63.617363"}
{"text": "However , the analysis and reporting of weight loss data in aggregate can obscure individual responses to treatment .Our study is the first study to describe weight loss variability with a GLP-1 receptor agonist and demonstrates that a subset of women have a robust response to exenatide treatment that can be identified very early in the course of therapy .", "label": "", "metadata": {}, "score": "63.643433"}
{"text": "All subjects who had a modified titration schedule during exenatide treatment reported nausea .Four subjects had a slower titration to the 10-\u03bcg dosage , and six subjects did not titrate above 7.5 \u03bcg .", "label": "", "metadata": {}, "score": "63.64823"}
{"text": "Gustavson SM , Chen D , Somayaji V , et al .Effects of a long - acting GLP-1 mimetic ( PF-04603629 ) on pulse rate and diastolic blood pressure in patients with type 2 diabetes mellitus .", "label": "", "metadata": {}, "score": "63.662556"}
{"text": "While there is no evidence to date that these agents ( short - acting or long - acting ) increase cardiovascular event rates , safety data are limited by short follow - up duration .", "label": "", "metadata": {}, "score": "63.6896"}
{"text": "The improvements in A1C for liraglutide - treated subjects receiving prestudy OAD monotherapy were greater ( decrease of 1.3 % for 1.8 mg liraglutide ) than the improvements for subjects with prestudy oral combination therapy ( decrease of 0.8 % , 1.8 mg liraglutide , significance not tested ) .", "label": "", "metadata": {}, "score": "63.790436"}
{"text": "At these dosage levels , the effect of liraglutide was comparable with that of glimepiride with respect to effect on HbA 1c .The effect of liraglutide increased with duration of treatment .", "label": "", "metadata": {}, "score": "63.88681"}
{"text": "The Baseline body weight value is defined as the last non - missing value before the start of treatment .Change from Baseline was calculated as the body weight value at Week 24 minus the value at Baseline .", "label": "", "metadata": {}, "score": "63.898087"}
{"text": "The degree of weight loss could be stratified .Waist circumference also decreased significantly with exenatide treatment .Subjects experienced more nausea during exenatide treatment compared with placebo , but the severity decreased over time and did not correlate with weight loss .", "label": "", "metadata": {}, "score": "63.95308"}
{"text": "The Baseline HbA1c value is defined as the last non - missing value on or before the start of treatment .Change from Baseline was calculated as the value at Week 52 minus the value at Baseline .", "label": "", "metadata": {}, "score": "64.061386"}
{"text": "Subjects will be randomly assigned to open - label liraglutide for 52 weeks .Drug : Liraglutide 0.9 mg daily .Liraglutide will be available as prefilled multidose pens that can deliver 0.9 mg dose .", "label": "", "metadata": {}, "score": "64.083244"}
{"text": "This combination significantly improved glycemic control and other efficacy parameters , in addition to resulting in significant weight loss and improved blood pressure .Acknowledgments .", "label": "", "metadata": {}, "score": "64.23988"}
{"text": "At the moment four different compounds are available for the treatment of T2D and many more are in clinical development .These compounds , although all based on the effects of native GLP-1 , differ with regards to structure , pharmacokinetics and size , which ultimately leads to different clinical effects .", "label": "", "metadata": {}, "score": "64.28935"}
{"text": "Change From Baseline in Fasting Plasma Glucose ( FPG ) at Week 52 [ Time Frame : Baseline and Week 52 ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "64.291534"}
{"text": "Gardiner SM , March JE , Kemp PA , et al .Autonomic nervous system - dependent and - independent cardiovascular effects of exendin-4 infusion in conscious rats .", "label": "", "metadata": {}, "score": "64.30804"}
{"text": "Methodological quality and risk of bias .Results of risk of bias assessment are given in table 2 .Explanation of sequence generation and allocation concealment was adequate for all trials .", "label": "", "metadata": {}, "score": "64.35454"}
{"text": "Page 15 . participants with type 2 diabetes .Cardiovasc Diabetol 2011;10:22 - 32 .Higgins JPT , Green S Cochrane handbook for systematic reviews of interventions .", "label": "", "metadata": {}, "score": "64.513405"}
{"text": "Lindholm A , Jensen LB , Home PD , Raskin P , Boehm BO , Rastam J : Immune responses to insulin aspart and biphasic insulin aspart in people with type 1 and type 2 diabetes .", "label": "", "metadata": {}, "score": "64.58978"}
{"text": "An oral antidiabetes drug ( OAD ) such as metformin is commonly used in first - line pharmacotherapy for type 2 diabetes .Sulfonylureas and thiazolidinediones are alternative OAD therapies , but both can elicit weight gain , whereas sulfonylureas can elicit hypoglycemia .", "label": "", "metadata": {}, "score": "64.70328"}
{"text": "Forty - three obese , diabetic and hypogonadal men ( aged 45 - 59 years ) were evaluated because of complaining about the recent onset of ED .", "label": "", "metadata": {}, "score": "64.754135"}
{"text": "In this 28-day study , adding exenatide to the existing treatment two or three times daily showed a significant effect in controlling patients ' HbA 1c levels , which were previously not satisfactorily controlled with diet and/or OHAs .", "label": "", "metadata": {}, "score": "64.88311"}
{"text": "Derosa G , Maffioli P , Salvadeo SA , et al .Exenatide vs. glibenclamide in patients with diabetes .Diabetes Technol Therap 2010;12:233 - 40 .", "label": "", "metadata": {}, "score": "64.96958"}
{"text": "( 12 ) demonstrated that exenatide with or without metformin was associated with greater weight loss as compared with metformin alone in their study of women with polycystic ovarian syndrome .", "label": "", "metadata": {}, "score": "65.021164"}
{"text": "Gutzwiller JP , Drewe J , Goke B , Schmidt H , Rohrer B , Lareida J , Beglinger C : Glucagon - like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2 .", "label": "", "metadata": {}, "score": "65.06096"}
{"text": "Ratner R , Han J , Nicewarner D , et al .Cardiovascular safety of exenatide BID : an integrated analysis from controlled clinical trials in 14 Robinson LE , Holt TA , Rees K , et al .", "label": "", "metadata": {}, "score": "65.06901"}
{"text": "Subjects will be randomly assigned to double blind albiglutide 30 mg weekly treatment for 52 weeks .Drug : Albiglutide 30 mg weekly .Albiglutide will be available as a pen injector that delivers 30 mg of albiglutide .", "label": "", "metadata": {}, "score": "65.082886"}
{"text": "Therefore , liraglutide - associated improvement in peripheral insulin resistance may be predominantly attributable to weight loss rather than an independent effect of GLP-1 action .", "label": "", "metadata": {}, "score": "65.276764"}
{"text": "Intervention : Drug : placebo .Not Provided .Terminated .Enrollment ICMJE .Completion Date .June 2013 .Primary Completion Date .June 2013 ( final data collection date for primary outcome measure ) .", "label": "", "metadata": {}, "score": "65.296684"}
{"text": "Treatment often must be intensified over time , usually by a combination of agents that address both insulin resistance and \u03b2 - cell dysfunction ( 1 , 2 ) .", "label": "", "metadata": {}, "score": "65.42"}
{"text": "Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin .", "label": "", "metadata": {}, "score": "65.68877"}
{"text": "Greater than 20 % attrition and higher attrition in the exenatide group 4 Greater than 20 % attrition .Outcome assessors unblinded after finalisation of the analysis plan 5 Greater than 20 % attrition .", "label": "", "metadata": {}, "score": "65.824844"}
{"text": "This study may demonstrate an important beta - cell protective capacity of liraglutide .Allocation : Randomized Endpoint Classification : Efficacy Study Intervention Model : Parallel Assignment Masking : Double Blind ( Subject , Caregiver , Investigator , Outcomes Assessor ) Primary Purpose : Treatment .", "label": "", "metadata": {}, "score": "65.83037"}
{"text": "At randomization , fasting blood glucose had to be 6 - 13 mmol / l .In total , 311 patients were screened and 193 patients were randomized to a treatment group ( Table 1 ) .", "label": "", "metadata": {}, "score": "65.924995"}
{"text": "OBJECTIVE To investigate the effect of treatment with the glucagon - like peptide 1 receptor agonist exenatide on weight loss and metabolic parameters in obese nondiabetic women .", "label": "", "metadata": {}, "score": "65.94904"}
{"text": "The Baseline FPG value is defined as the last non - missing value on or before the start of treatment .Change from Baseline was calculated as the FPG value at Week 52 minus the FPG value at Baseline .", "label": "", "metadata": {}, "score": "65.95727"}
{"text": "Other gastrointestinal events included diarrhea ( 5 of 135 liraglutide - treated patients ) , vomiting ( 3 of 135 patients ) , and constipation ( 3 of 135 patients ) .", "label": "", "metadata": {}, "score": "65.96231"}
{"text": "There was no significant change in quantitative or qualitative physical activity , nor was there a difference in sleep parameters , including sleep duration , sleep efficiency , or wake after sleep onset .", "label": "", "metadata": {}, "score": "65.972244"}
{"text": "Larsen J , Hylleberg B , Ng K , Damsbo P : Glucagon - like peptide-1 infusion must be maintained for 24 h / day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulfonylurea treatment .", "label": "", "metadata": {}, "score": "66.04206"}
{"text": "34 - 41 This left 32 trials included in our review ( figure 1 and table 1 ) .42 - 73 Most studies did not report all of the outcomes of interest , or they did not provide them as usable numerical data .", "label": "", "metadata": {}, "score": "66.1995"}
{"text": "Adverse events with the drug are mild and transient , and the risk of hypoglycemia is negligible .Type 2 diabetes is characterized by insulin resistance and defective \u03b2 - cell function and is associated with hyperglucagonemia , increased hepatic glucose production , and obesity ( 1 ) .", "label": "", "metadata": {}, "score": "66.24455"}
{"text": "Change from Baseline was calculated as the body weight value at Week 52 minus the value at Baseline .Time to Study Withdrawal Due to Hyperglycemia [ Time Frame : Baseline through Week 52 ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "66.24548"}
{"text": "This ratio is known to be elevated in type 2 diabetes and is considered an index of insulin secretory dysfunction ( 24 , 25 ) .", "label": "", "metadata": {}, "score": "66.31012"}
{"text": "Hypoglycemia was not observed in the fasting state or during oral glucose tolerance tests .The most common adverse event was nausea .A total of 56 % of subjects experienced one or more episodes of nausea during exenatide treatment compared with 21 % of subjects during placebo treatment .", "label": "", "metadata": {}, "score": "66.32626"}
{"text": "Robinson LE , Holt TA , Rees K , et al .BMJ Open 2013;3:e001986 .Page 8 . oral anti - diabetic drug ( OAD ) or insulin , were included .", "label": "", "metadata": {}, "score": "66.35354"}
{"text": "Information on the participants , intervention , compari- son group , outcomes and trial quality was extracted from included studies by two researchers independently .Figure 4 ( Continued ) 8 Robinson LE , Holt TA , Rees K , et al .", "label": "", "metadata": {}, "score": "66.38559"}
{"text": "Injected subcutaneously(under the skin ) once daily .Drug : placebo .Dose escalation escalation of liraglutide up to 1.2 to 1.8 mg before islet cell transplant until the planned number of transplanted subjects is complete or subject is transplanted .", "label": "", "metadata": {}, "score": "66.40486"}
{"text": "Parts of this study were presented as a poster at the 68th annual meeting of the American Diabetes Association , San Francisco , California , 6 - 10 June 2008 .", "label": "", "metadata": {}, "score": "66.48173"}
{"text": "Weight loss associated with liraglutide treatment led to a 29 % reduction in peripheral insulin resistance .As discussed , we are not aware of another study that has measured peripheral insulin resistance using a direct method after liraglutide treatment in the prediabetes population .", "label": "", "metadata": {}, "score": "66.54602"}
{"text": "Subjects will be randomly assigned to double blind albiglutide 50 mg weekly until Week 52 .Drug : Albiglutide 50 mg weekly .Albiglutide will be available as a pen injector that delivers 50 mg of albiglutide .", "label": "", "metadata": {}, "score": "66.60055"}
{"text": "Article focus .Glucagon - like peptide-1 ( GLP-1 ) agonists are increasingly used in the management of type 2 diabetes , but their long - term cardiovascular safety is not yet confirmed .", "label": "", "metadata": {}, "score": "66.69901"}
{"text": "Effects of exenatide ( exendin-4 ) on glycemic control over 30 weeks in sulfonylurea - treated patients with type 2 diabetes .Diabetes Care 2004 ; 27 : 2628 - 2635 pmid : 15504997 .", "label": "", "metadata": {}, "score": "66.762985"}
{"text": "The mechanisms of weight loss with exenatide are not fully understood but may include changes in energy expenditure , changes in leptin sensitivity , or nausea resulting in decreased food intake .", "label": "", "metadata": {}, "score": "66.7975"}
{"text": "TZD treatment is associated with a modest reduction in blood pressure but is also associated with fluid retention .There may be an interaction between the cardiovascular effects of liraglutide and TZD .", "label": "", "metadata": {}, "score": "67.14554"}
{"text": "A Randomized Controlled Study Assessing the Effect of Liraglutide on the Preservation of Beta - Cell Function in Patients With Type 2 Diabetes Mellitus : The LIraglutide and Beta - cell RepAir ( LIBRA ) Study .", "label": "", "metadata": {}, "score": "67.1519"}
{"text": "D : Change in body weight over time .E : SBP over time .F : Percentage of subjects with nausea by week .Data are intent to treat , last observation carried forward for all postbaseline values , with the exception of F , which is data from the safety analysis set .", "label": "", "metadata": {}, "score": "67.16704"}
{"text": "Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes ( DURATION 3 ) : An open - label randomised trial .", "label": "", "metadata": {}, "score": "67.397835"}
{"text": "Mean change in body weight over time is shown in Fig . 1 D .There were no significant differences between treatment groups in diastolic blood pressure ( DBP ) .", "label": "", "metadata": {}, "score": "67.42346"}
{"text": "Association of average heart rate on 24-hour ambulatory electrocardiograms with incidence of new coronary events at 48-month follow - up in 1311 patients ( mean age 81 years ) with heart disease and sinus rhythm .", "label": "", "metadata": {}, "score": "67.452156"}
{"text": "BMJ Open 2013;3:e001986 .doi:10.1136/bmjopen-2012 - 001986 3 Meta - analysis of effects of GLP-1 on heart rate , blood pressure and body weight .", "label": "", "metadata": {}, "score": "67.54531"}
{"text": "Individuals were advised to maintain their baseline physical activity .After 12 weeks , subjects were advised to maintain their weight for 2 weeks before end - of - study testing .", "label": "", "metadata": {}, "score": "67.58775"}
{"text": "Change in HbA1c ( glycosylated haemoglobin A1c )[ Time Frame : at week 52 ] [ Designated as safety issue : No ] .Number of Hypoglycaemic Episodes [ Time Frame : During weeks 0 - 52 ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "67.70868"}
{"text": "One death ( cardiorespiratory arrest ) was reported during the trial and occurred during the metformin run - in period , before randomization to treatment .", "label": "", "metadata": {}, "score": "67.712906"}
{"text": "Griffioen KJ , Wan R , Okun E , et al .GLP-1 receptor stimulation depresses heart rate variability and inhibits neurotransmission to cardiac vagal neurons .", "label": "", "metadata": {}, "score": "67.71823"}
{"text": "Blonde L , Russell - Jones D. The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes : an overview of the LEAD 1 - 5 studies .", "label": "", "metadata": {}, "score": "67.78146"}
{"text": "Agers\u00f8 H , Jensen LB , Elbr\u00f8nd B , Rolan P , Zdravkovic M : The pharmacokinetics , pharmacodynamics , safety and tolerability of NN2211 , a new long - acting GLP-1 derivative , in healthy men .", "label": "", "metadata": {}, "score": "67.834915"}
{"text": "Attrition was adequately described and was greater than 20 % in nine studies .The proportion of the intention - to - treat population completing the study varied in range 65.4 - 99.6 % and had a median of 83.7 % .", "label": "", "metadata": {}, "score": "67.856346"}
{"text": "Differing provisions from the publisher 's actual policy or licence agreement may be applicable .\"Conversely , those subjects who reached the glycaemic target were not added other drugs but exclusively observed for another year ( T3 )", "label": "", "metadata": {}, "score": "67.89569"}
{"text": "Parts of this study were presented in abstract form at the Obesity Society 28th Annual Scientific Meeting , San Diego , California , 8 - 12 October 2010 .", "label": "", "metadata": {}, "score": "67.925354"}
{"text": "The dose was decreased by 0.6-mg increments for intolerable side effects .Subjects were seen by a study personnel and a research dietitian weekly for the first 4 weeks , and then every 2 weeks .", "label": "", "metadata": {}, "score": "67.938675"}
{"text": "Page 9 .Where necessary , clarification of data was obtained by correspondence with trial co - ordinators .Analysis Means and SDs for baseline and outcome values for blood pressure , heart rate and body weight were extracted .", "label": "", "metadata": {}, "score": "67.97626"}
{"text": "Missing data were imputed as the last observation carried forward .Sample size calculations were based on showing A1C and body weight differences of 0.5 and 3 % , respectively .", "label": "", "metadata": {}, "score": "68.03483"}
{"text": "Primary Purpose : Treatment .Official Title : .A Randomized , Double - Blind , Placebo - Controlled , Parallel Group , Multicenter Monotherapy Study to Determine the Efficacy and Safety of 2 Dose Levels of Albiglutide in Subjects With Type 2 Diabetes Mellitus .", "label": "", "metadata": {}, "score": "68.106964"}
{"text": "No major hypoglycemic event was reported .No clinically relevant between - treatment differences were observed in physical examination findings , laboratory analyses ( hematology and biochemistry analyses ) , electrocardiogram , or ophthalmoscopy .", "label": "", "metadata": {}, "score": "68.2404"}
{"text": "REFERENCES 1 .Nathan DM , Buse JB , Davidson MB , et al .Medical management of hyperglycemia in type 2 diabetes : a consensus algorithm for the initiation and adjustment of therapy .", "label": "", "metadata": {}, "score": "68.26843"}
{"text": "The review is up to date at July 2012 .Inclusion and exclusion criteria .Participants : We only included trials involving participants with type 2 diabetes .", "label": "", "metadata": {}, "score": "68.34569"}
{"text": "This technique could be used as a basis for a larger study powered to detect such a difference and to investigate the influence of alternative background medications .", "label": "", "metadata": {}, "score": "68.71893"}
{"text": "Liraglutide ( active or placebo ) was injected subcutaneously once daily at any time of the day in the upper arm , abdomen , or thigh using a prefilled pen device .", "label": "", "metadata": {}, "score": "68.731125"}
{"text": "Glucagon - like peptide-1-responsive catecholamine neurons in the area postrema link peripheral glucagon - like peptide-1 with central autonomic control sites .J Neurosci 2003 ; 23 : 2939 - 2946 pmid : 12684481 BMJ Open ( Impact Factor : 2.27 ) . 01/2013 ; BMJ Open 2013;3:e001986 .", "label": "", "metadata": {}, "score": "68.9491"}
{"text": "Minor hypoglycemic episodes were self - treated ; major episodes required third - party assistance .Statistical analysis .The analyses of efficacy end points were based on the intent - to - treat population defined as subjects who were exposed to at least one dose of trial product and had one postbaseline measurement of the parameter .", "label": "", "metadata": {}, "score": "69.181656"}
{"text": "Charbonnel B , Karasik A , Liu J , Wu M , Meininger G , Sitagliptin Study 020 Group : Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy .", "label": "", "metadata": {}, "score": "69.23007"}
{"text": "Weight change with liraglutide and comparator therapies : an analysis of seven phase 3 trials from the liraglutide diabetes development programme .Diabetes Obes Metab 2013 ; 15 : 42 - 54 pmid : 22862847", "label": "", "metadata": {}, "score": "69.28779"}
{"text": "National Institute for Health and Clinical Excellence .Technology Appraisal TA248 .Exenatide prolonged - release suspension for injection in combination with oral antidiabetic therapy for the treatment of type 2 diabetes .", "label": "", "metadata": {}, "score": "69.33225"}
{"text": "National Institute for Health and Clinical Excellence .Technology Appraisal TA248 .Exenatide prolonged - release suspension for injection in combination with oral antidiabetic therapy for the treatment of type 2 diabetes .", "label": "", "metadata": {}, "score": "69.33225"}
{"text": "Nauck MA , Wollschlager D , Werner J , Holst JJ , Orskov C , Creutzfeldt W , Willms B : Effects of subcutaneous glucagon - like peptide 1 ( GLP-1 [ 7 - 36 amide ] ) in patients with NIDDM .", "label": "", "metadata": {}, "score": "69.36487"}
{"text": "In all , 190 patients were exposed to the experimental protocol ; 3 patients withdrew consent before receiving randomized treatment .Patients were recruited from the participating investigators ' outpatient clinics or by local advertisements .", "label": "", "metadata": {}, "score": "69.41879"}
{"text": "Hypoglycemic episodes were analyzed using a general linear model including treatment as a fixed effect .RESULTS .Three subjects were randomized but were withdrawn before receiving the study drug .", "label": "", "metadata": {}, "score": "69.521965"}
{"text": "Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure ( EUREXA ) : an open - label , randomised controlled trial .", "label": "", "metadata": {}, "score": "69.531105"}
{"text": "Heart rate rises were more evident for liraglutide than exenatide , and for exenatide long - acting release than exenatide twice daily .Strengths and limitations .", "label": "", "metadata": {}, "score": "69.64181"}
{"text": "Diet and exercise regimes not standardised 25 Open label 26 Higher attrition in the liraglutide 1.8 mg and placebo arms 27Open label , but statistician was masked to the allocation 28 Insulin glargine arm - open label 29 30 Higher attrition in the liraglutide groups 31 Greater than 20 % attrition .", "label": "", "metadata": {}, "score": "69.94664"}
{"text": "Matthews DR , Hosker JP , Rudenski AS , Naylor BA , Treacher DF , Turner RC : Homeostasis model assessment : insulin resistance and beta - cell function from fasting plasma glucose and insulin concentrations in man .", "label": "", "metadata": {}, "score": "69.98831"}
{"text": "Am J Cardiol 1996;78:1175 - 6 .Hozawa A , Ohkubo T , Kikuya M , et al .Prognostic value of home heart rate for cardiovascular mortality in the general population : the Ohasama study .", "label": "", "metadata": {}, "score": "70.1763"}
{"text": "Page 3 .Table 1 Characteristics of included studies Study Apovian et al42 Barnett et al43 Bergenstal et al44 Bergenstal et al45 Comparisons Duration ( weeks )", "label": "", "metadata": {}, "score": "70.234924"}
{"text": "One preclinical study also has suggested that GLP-1 action may reduce central parasympathetic outflow to cardiac vagal neurons ( 26 ) .The major limitation of our study was that the experimental groups were relatively small .", "label": "", "metadata": {}, "score": "70.26306"}
{"text": "Knudsen LB , Nielsen PF , Huusfeldt PO , Johansen NL , Madsen K , Pedersen FZ , Thogersen H , Wilken M , Agerso H : Potent derivatives of glucagon - like peptide-1 with pharmacokinetic properties suitable for once daily administration .", "label": "", "metadata": {}, "score": "70.27519"}
{"text": "Anselmino M , \u00d6hrvik J , Ryd\u00e9n L. Resting heart rate in patients with stable coronary artery disease and diabetes : a report from the euro heart survey on diabetes and the heart .", "label": "", "metadata": {}, "score": "70.3398"}
{"text": "Endocrin Prac 2011;17:192 - 200 .Bojanowska E , Stempniak B. Effects of glucagon - like peptide-1 ( 7 - 36 ) amide on neurohypophysial hormone secretion induced by acute hyperosmotic challenge .", "label": "", "metadata": {}, "score": "70.34863"}
{"text": "The specific mechanism(s ) of SBP reduction and the slight increases in pulse with liraglutide remain to be further studied .Based on data with native GLP-1 , it could be speculated that the effect on SBP relates to reduced renal sodium reabsorption ( 16 , 17 ) .", "label": "", "metadata": {}, "score": "70.42873"}
{"text": "Lifestyle modification and prevention of type 2 diabetes in overweight Japanese with impaired fasting glucose levels : a randomized controlled trial .Arch Intern Med 2011 ; 171 : 1352 - 1360 pmid : 21824948 .", "label": "", "metadata": {}, "score": "70.52367"}
{"text": "Although many studies have shown that weight loss can be achieved through highly supervised dietary interventions , weight regain following these interventions is almost universal ( 2 - 4 ) .", "label": "", "metadata": {}, "score": "70.567635"}
{"text": "Major exclusion criteria included having type 1 or type 2 diabetes , having uncontrolled hypertension or dyslipidemia , being treated with antiobesity medication within 1 year , having a history of bariatric surgery , and having previous treatment with exenatide .", "label": "", "metadata": {}, "score": "70.63074"}
{"text": "Meier JJ , Nauck MA .Glucagon - like peptide 1(GLP-1 ) in biology and pathology .Diabetes Metab Res Rev 2005;21:91 - 117 .Varanasi A , Chaudhuri A , Dhindsa S , et al .", "label": "", "metadata": {}, "score": "70.83999"}
{"text": "The use of this triple therapy has demonstrated the largest decreases in A1C and SBP values in the LEAD program .Exenatide , a commercially available GLP-1 receptor agonist , is a synthetic version of exendin-4 .", "label": "", "metadata": {}, "score": "70.89828"}
{"text": "Bharucha AE , Charkoudian N , Andrews CN , et al .Effects of glucagon - like peptide-1 , yohimbine , and nitrergic modulation on sympathetic and parasympathetic activity in humans .", "label": "", "metadata": {}, "score": "71.10309"}
{"text": "In our paper we discuss special features of combinations of short- or prandial - acting and long- or continuous - acting GLP-1 RAs like exenatide , lixisenatide and liraglutide with basal insulin in relation to different glycemic targets .", "label": "", "metadata": {}, "score": "71.27713"}
{"text": "For example , liraglutide treatment can improve glucose tolerance by enhancing glucose - stimulated insulin secretion rate ( 20 ) .In the current study , liraglutide treatment was associated with a 0.5-mmol / L decrease in fasting glucose concentration .", "label": "", "metadata": {}, "score": "71.359985"}
{"text": "Exenatide twice daily versus premixed insulin aspart 70/30 in metformin - treated patients with type 2 diabetes : a randomized 26-week study on glycemic control and hypoglycaemia .", "label": "", "metadata": {}, "score": "71.54852"}
{"text": "All patients were asked to fill in the International Index of Erectile Function ( IIEF 15 ) questionnaire before starting TU plus Met ( T1 ) and after 12 months ( T2 ) and 24 months ( T3 ) of treatment .", "label": "", "metadata": {}, "score": "71.552124"}
{"text": "The underlying pathophysiology of type 2 diabetes is complex and involves three main factors : a relative decrease in \u03b2 - cell insulin secretory function ; increased glucose production by the liver , which is at least partially mediated by inappropriately increased glucagon levels ; and decreased glucose uptake by muscle .", "label": "", "metadata": {}, "score": "71.77732"}
{"text": "Verdich C , Flint A , Gutzwiller JP , Naslund E , Beglinger C , Hellstrom PM , Long SJ , Morgan LM , Holst JJ , Astrup A : A meta - analysis of the effect of glucagon - like peptide-1 ( 7 - 36 ) amide on ad libitum energy intake in humans .", "label": "", "metadata": {}, "score": "71.79939"}
{"text": "The full dosage - response curve for liraglutide remains to be elucidated , and future trials will investigate higher dosages of drug , but the current trial confirmed the proposed once - daily dosing regimen for liraglutide .", "label": "", "metadata": {}, "score": "71.83122"}
{"text": "Risk of bias .23 Funnel plots were used to detect publication bias .Analysis .Means and SDs for baseline and outcome values for blood pressure , heart rate and body weight were extracted .", "label": "", "metadata": {}, "score": "72.02917"}
{"text": "Safety parameters ( adverse events , hypoglycemic episodes , weight , standard hematology and biochemistry profile , vital signs , and electrocardiogram ) were assessed at each visit .", "label": "", "metadata": {}, "score": "72.08807"}
{"text": "Statistical analysis .The analysis of efficacy end points was based on the intent - to - treat population , defined as subjects who were exposed to at least one dose of trial product and had one postbaseline measurement of the parameter .", "label": "", "metadata": {}, "score": "72.09657"}
{"text": "Datafrom the tide57 64 67 69 73were initially grouped into quartiles of baseline heart rate and demonstrated significant varia- tions in effect between these subgroups , with the great- est increase seen in those with the lowest baseline values .", "label": "", "metadata": {}, "score": "72.20094"}
{"text": "Mari A , Degn K , Brock B , Rungby J , Ferrannini E , Schmitz O : Effects of the long - acting human glucagon - like peptide-1 analog liraglutide on \u03b2 - cell function in normal living conditions .", "label": "", "metadata": {}, "score": "72.50191"}
{"text": "Lipid panels , leptin , and adiponectin were measured after an overnight fast at weeks 0 , 10 , and 16 during both treatment periods .", "label": "", "metadata": {}, "score": "72.59715"}
{"text": "Levine HJ .Rest heart rate and life expectancy .J Am Coll Cardiol 1997;30:1104 - 6 .Aronow WS , Ahn C , Mercando AD , et al .", "label": "", "metadata": {}, "score": "72.81933"}
{"text": "Naslund E , Barkeling B , King N , Gutniak M , Blundell JE , Holst JJ , Rossner S , Hellstrom PM : Energy intake and appetite are suppressed by glucagon - like peptide-1 ( GLP-1 ) in obese men .", "label": "", "metadata": {}, "score": "72.96913"}
{"text": "Subjects were excluded if they had used insulin during the previous 3 months ( except short - term treatment ) .The protocol was approved by local institutional review boards , and all subjects provided written informed consent before initiation of any trial - related activities .", "label": "", "metadata": {}, "score": "72.999535"}
{"text": "Data were there- foreobtained , where available , pharmaceutical companies .directlyfromthe Methodological quality and risk of bias Results of risk of bias assessment are given in table 2 .", "label": "", "metadata": {}, "score": "73.04202"}
{"text": "This article must therefore be hereby marked \" advertisement \" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact .Meier JJ , Nauck MA , Kranz D , Holst JJ , Deacon CF , Gaeckle D , Schmidt WE , Gallwitz B : Secretion , degradation , and elimination of glucagon - like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects .", "label": "", "metadata": {}, "score": "73.04648"}
{"text": "The latter has also been shown for liraglutide ( 20 ) .Potentially , the slight increases in pulse observed with liraglutide may be compensatory for the decreases in SBP .", "label": "", "metadata": {}, "score": "73.07768"}
{"text": "Bregenholt S , Moldrup A , Blume N , Karlsen AE , Friedrichsen BN , Tornhave D , Knudsen LB , Petersen JS : The long - acting glucagon - like peptide-1 analogue , liraglutide , inhibits \u03b2 - cell apoptosis in vitro .", "label": "", "metadata": {}, "score": "73.28298"}
{"text": "clinicaltrials.gov ) ; Entertrials.co.uk ; Clinicaltrialssearch .Figure 1 PRISMA flow diagram .GLP-1 , glucagon - like peptide-1 .2 Robinson LE , Holt TA , Rees K , et al .", "label": "", "metadata": {}, "score": "73.49042"}
{"text": "Liraglutide is a human GLP-1 analog with 97 % homology to native GLP-1 ( 5 ) .Liraglutide has a half - life in humans of 13 h compared with 1 - 2 min for native GLP-1 , making liraglutide suitable as a once - daily treatment for patients with type 2 diabetes ( 6 ) .", "label": "", "metadata": {}, "score": "74.08504"}
{"text": "Conclusions GLP-1 analogues are associated with a small increase in heart rate and modest reductions in body weight and blood pressure .Mechanisms underlying the rise in heart rate require further investigation .", "label": "", "metadata": {}, "score": "74.17621"}
{"text": "Conclusions GLP-1 analogues are associated with a small increase in heart rate and modest reductions in body weight and blood pressure .Mechanisms underlying the rise in heart rate require further investigation .", "label": "", "metadata": {}, "score": "74.17621"}
{"text": "Dietary or pharmacologic interventions that blunt the decrease in REE with weight loss are in great clinical demand .We identified a potential effect of exenatide on REE because those who had the most robust weight loss with exenatide did not have the expected decrease in this parameter .", "label": "", "metadata": {}, "score": "74.50952"}
{"text": "We aimed to identify and synthesise all available heart rate data from both published and unpublished sources to quantify the effect of GLP-1 analogues on heart rate , as well as that on blood pressure and body weight .", "label": "", "metadata": {}, "score": "74.697685"}
{"text": "RESULTS Figure 1 describes the identification of the studies included .A total of 521 articles were screened .Of these , 472 were excluded on the basis of the title or abstract being irrelevant to the aims of this review .", "label": "", "metadata": {}, "score": "74.70904"}
{"text": "RESEARCH DESIGN AND METHODS .This trial was a 12-week , multicenter , double - blind , randomized , parallel - group , dosage - response trial in six treatment arms .", "label": "", "metadata": {}, "score": "75.157005"}
{"text": "Subjects previously treated with pioglitazone underwent rosiglitazone titration ( by transferring to the corresponding rosiglitazone dose ) or went directly to the maximum dose if they were on the maximum pioglitazone dose .", "label": "", "metadata": {}, "score": "75.48168"}
{"text": "Vilsboll T , Christensen M , Junker AE , et al .Effects of glucagon - like peptide receptor agonists on weight loss : systematic review and meta - analyses of randomized controlled trials .", "label": "", "metadata": {}, "score": "75.800835"}
{"text": "A difference of 20 % was chosen because this is the degree of difference in SSPG concentration seen with modest weight loss of 7 % ( 17 ) .", "label": "", "metadata": {}, "score": "75.91686"}
{"text": "Another mechanism through which exenatide may produce weight loss is by increasing leptin sensitivity .Obesity is considered to be a state of leptin resistance , and weight loss is thought to improve leptin sensitivity .", "label": "", "metadata": {}, "score": "76.092316"}
{"text": "The Cochrane Collaboration , 2011 .Follman D , Elliott P , Suh I , et al .Variance imputation for overviews of clinical trials with continuous response .", "label": "", "metadata": {}, "score": "76.19026"}
{"text": "The review is up to date at July 2012 .Inclusion and exclusion criteria A. Participants : We only included trials involving partici- pants with type 2 diabetes .", "label": "", "metadata": {}, "score": "76.200874"}
{"text": "While a number of studies have reported heart rate increases , the associated mechanisms are unknown , and this effect is often dismissed as clinically unimportant .", "label": "", "metadata": {}, "score": "76.21045"}
{"text": "Liraglutide , a glucagon - like peptide 1 ( GLP-1 ) analog , is approved for the treatment of T2DM .In addition to improving glucose tolerance , GLP-1 action has been associated with weight loss in individuals with T2DM ( 9 ) .", "label": "", "metadata": {}, "score": "76.22439"}
{"text": "Written informed consent was obtained from all individuals .The protocol was approved by the Stanford Institutional Review Board .Procedures .We conducted a double - blind , randomized , placebo - controlled study of liraglutide .", "label": "", "metadata": {}, "score": "76.47812"}
{"text": "74 , 75 The heart rate response in the presence or absence of autonomic neuropathy in human patients might therefore justify further study .There is also a clear need to improve the comprehensive reporting of all outcome data measured during clinical trials of antidiabetic agents , particularly those relevant to cardiovascular risk .", "label": "", "metadata": {}, "score": "76.583275"}
{"text": "We have derived a similar Figure 6 GLP-1 agonists ' effects on body weight .GLP-1 , glucagon - like peptide-1 .Robinson LE , Holt TA , Rees K , et al .", "label": "", "metadata": {}, "score": "76.74988"}
{"text": "U.K. Prospective Diabetes Study ( UKPDS )Group : Intensive blood - glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes ( UKPDS 33 ) .", "label": "", "metadata": {}, "score": "76.75318"}
{"text": "Serum insulin and C - peptide values were determined using a chemiluminescence immunoassay , and proinsulin was measured in serum using an enzyme - linked immunosorbent assay .", "label": "", "metadata": {}, "score": "76.9093"}
{"text": "Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients .Eur J Pharmacol 2011;666:251 - 6 .", "label": "", "metadata": {}, "score": "76.93518"}
{"text": "Flint A , Raben A , Astrup A , et al .Glucagon - like peptide 1 promotes satiety and suppresses energy intake in humans .", "label": "", "metadata": {}, "score": "76.98903"}
{"text": "Accordingly , the intent - to - treat and safety ( all subjects exposed to study drug ) populations comprised 1,087 subjects and are summarized by treatment group in Table 1 .", "label": "", "metadata": {}, "score": "76.99036"}
{"text": "MacDonald PE , El - kholy W , Riedel MJ , et al .The multiple actions of GLP-1 on the process of glucose - stimulated insulin secretion .", "label": "", "metadata": {}, "score": "77.01605"}
{"text": "Results .Figure 1 describes the identification of the studies included .A total of 521 articles were screened .Of these , 472 were excluded on the basis of the title or abstract being irrelevant to the aims of this review .", "label": "", "metadata": {}, "score": "77.197716"}
{"text": "Both autonomic nervous system - dependent and system - independent effects have been suggested in animal studies as a basis for the rise in heart rate.74 75The heart rate response in the pres- ence or absence of autonomic neuropathy in human patients might therefore justify further study .", "label": "", "metadata": {}, "score": "77.203514"}
{"text": "In circulation , GLP-1 has a half - life of approximately 2 min due to rapid degradation by the enzyme dipeptidyl peptidase 4 ( DPP-4 ) .", "label": "", "metadata": {}, "score": "77.36102"}
{"text": "A : A1C over time for the study population .B : Percentage of subjects achieving ADA and AACE / IDF A1C goals at the end of the study .", "label": "", "metadata": {}, "score": "77.65817"}
{"text": "Adverse events were isolated , with the most frequent being headache and nausea .Usually the events were transient and of mild or moderate severity and resolved without intervention .", "label": "", "metadata": {}, "score": "77.88602"}
{"text": "Liraglutide is a human GLP-1 analog with 97 % homology to native GLP-1 ( 5 ) .The addition of a fatty acid ( palmitate ) side chain and a single amino acid substitution produces self - association of the molecule that prolongs absorption from the subcutaneous depot .", "label": "", "metadata": {}, "score": "78.131546"}
{"text": "Blood was drawn at 10-min intervals from 150 to 180 min of the infusion to determine the steady - state plasma glucose ( SSPG ) and insulin concentrations .", "label": "", "metadata": {}, "score": "78.15656"}
{"text": "Of these , four were Figure 5 ( Continued ) 10 Robinson LE , Holt TA , Rees K , et al .BMJ Open 2013;3:e001986 .", "label": "", "metadata": {}, "score": "78.23413"}
{"text": "Liraglutide was shown to be similar to glimepiride in improving HOMA - B values in the current study .Improvements in \u03b2 - cell function with liraglutide treatment have been observed in several other studies with liraglutide ( 10 , 20 , 21 ) .", "label": "", "metadata": {}, "score": "78.24315"}
{"text": "All statistical analyses were conducted using SPSS ( version 20 for Windows ; SPSS , Chicago , IL ) .Data are presented as mean \u00b1 SD unless otherwise specified .", "label": "", "metadata": {}, "score": "78.24821"}
{"text": "Retrieved studies were assessed for inclusion by two researchers independently using the above criteria , and any discrepancies were resolved by consensus .Information on the participants , intervention , comparison group , outcomes and trial quality was extracted from included studies by two researchers independently .", "label": "", "metadata": {}, "score": "78.418365"}
{"text": "Sulfonylureas , although efficient in stimulating insulin secretion and lowering blood glucose , pose the disadvantages of weight gain and risk of hypoglycemia ( 4 ) .", "label": "", "metadata": {}, "score": "78.41844"}
{"text": "Funnel plots were broadly symmetrical with no evidence of publication bias .Heterogeneity .The trials varied in terms of duration of follow - up , location , type of active comparator drug and background therapy .", "label": "", "metadata": {}, "score": "78.5878"}
{"text": "HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over a 2- to 3 month period .The Baseline HbA1c value is defined as the last nonmissing value before the start of treatment .", "label": "", "metadata": {}, "score": "78.69716"}
{"text": "A comparator group with calorie - restricted weight loss would help answer this question in future studies .Nausea , the most common adverse effect of exenatide , also may contribute to weight loss .", "label": "", "metadata": {}, "score": "78.74988"}
{"text": "Glucagon - like peptide-1 ( GLP-1 ) stimulates insulin secretion and suppression of glucagon secretion in a glucose - dependent manner , delays gastric emptying , and decreases appetite ( 4 ) .", "label": "", "metadata": {}, "score": "78.863434"}
{"text": "As seen in Table 1 , baseline characteristics were not different between the two groups .Thus , age ( mean , 58 years ) and BMI ( mean , 31.9 kg / m 2 ) were identical between the two groups .", "label": "", "metadata": {}, "score": "78.88724"}
{"text": "Exclusion Criteria : .Treatment with any anti - diabetic medication other than insulin including insulin pump within 4 weeks of trial start .Any previous organ transplantation .", "label": "", "metadata": {}, "score": "78.90344"}
{"text": "However , native GLP-1 has a very short half - life ( 1 min ) ( 12 ) , being rapidly metabolized by the enzyme dipeptidyl peptidase IV ( 13 ) .", "label": "", "metadata": {}, "score": "78.920654"}
{"text": "A crossover study design introduces the possibility of both an order effect and a carryover effect .Our statistical analysis was adjusted for possible treatment order effects .", "label": "", "metadata": {}, "score": "79.006546"}
{"text": "Deacon CF , Johnsen AH , Holst JJ : Degradation of glucagon - like peptide-1 by human plasma in vitro yields an N - terminally truncated peptide that is a major endogenous metabolite in vivo .", "label": "", "metadata": {}, "score": "79.53544"}
{"text": "Using an appropriately - sized cuff , three blood pressure and pulse readings were taken at 1-min intervals , and the mean of these readings was used for data analysis .", "label": "", "metadata": {}, "score": "79.6055"}
{"text": "BMJ Open 2013;3:e001986 .Page 2 .Given the safety implications attributed to raised heart rate in other contexts,10 - 13there is a surprising lack of concern over its possible implications in this setting .", "label": "", "metadata": {}, "score": "79.62311"}
{"text": "Deacon CF , Knudsen LB , Madsen K , Wiberg FC , Jacobsen O , Holst JJ : Dipeptidyl peptidase IV resistant analogues of GLP-1 which have extended metabolic stability and improved biological activity .", "label": "", "metadata": {}, "score": "79.62447"}
{"text": "Intensive blood - glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes ( UKPDS 33 ) .", "label": "", "metadata": {}, "score": "79.78227"}
{"text": "Change From Baseline in Body Weight at Week 52 [ Time Frame : Baseline and Week 52 ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "80.296974"}
{"text": "Peripheral insulin resistance was quantified by measuring the steady - state plasma glucose ( SSPG ) concentration during the insulin suppression test .Traditional CVD risk factors and inflammatory markers also were assessed .", "label": "", "metadata": {}, "score": "80.29753"}
{"text": "Injected subcutaneously ( under the skin ) once daily .Study Arm ( s ) .Experimental : Liraglutide .Intervention : Drug : liraglutide .", "label": "", "metadata": {}, "score": "80.50063"}
{"text": "Subjects were provided with MediSense Precision Xtra / MediSense Optium glucose meters ( Abbott , Maidenhead , U.K. ) calibrated to plasma glucose to determine self - measured plasma glucose and recorded values in their diaries .", "label": "", "metadata": {}, "score": "80.687256"}
{"text": "Exenatide compared with long - acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes : results of helping evaluate exenatide in patients with diabetes compared with long - acting insulin ( HEELA ) study .", "label": "", "metadata": {}, "score": "81.190414"}
{"text": "Measurement of heart rate using this 24 h technique ( compared with a traditional heart rate measurement in clinic ) substantially improves the accuracy of measurement as heart rate is very variable within the individual .", "label": "", "metadata": {}, "score": "81.66581"}
{"text": "A long - acting GLP-1 RA might well be given , if fasting blood glucose values are the problem .Based on pathophysiological findings , recent clinical studies and our experience with BIT and BOT as well as BOTplus we developed chart - supported algorithms for decision making , including features and conditions of patients .", "label": "", "metadata": {}, "score": "81.98371"}
{"text": "Blood pressure .We included 31 trials measuring blood pressure changes ( figures 4 and 5 ) .Body weight .Twenty - one trials measuring changes in weight were included ( figure 6 ) .", "label": "", "metadata": {}, "score": "82.09136"}
{"text": "Plasma glucagon was analyzed by MDS Pharma Services ( Wangen , Switzerland ) using a radioimmunoassay ( Linco Research , St. Charles , MO ) .", "label": "", "metadata": {}, "score": "82.44951"}
{"text": "While improvement in \u03b2 - cell function may have been a consequence of improved glucose control , it could well be a direct effect of liraglutide , which is known to stimulate glucose - dependent endogenous insulin secretion .", "label": "", "metadata": {}, "score": "83.22176"}
{"text": "Condition ICMJE .Diabetes .Diabetes Mellitus , Type 1 .Intervention ICMJE .Drug : liraglutide .Dose escalation of liraglutide up to 1.2 to 1.8 mg before islet cell transplant until the planned number of transplanted subjects is complete or subject is transplanted .", "label": "", "metadata": {}, "score": "83.23561"}
{"text": "The main side effects of exenatide are mild to moderate nausea , diarrhoea and vomiting .\" [ Show abstract ] [ Hide abstract ] ABSTRACT : Glucagon - like peptide-1 ( GLP-1 ) is a gastrointestinal hormone , secreted in response to ingestion of nutrients , and has important effects on several of the pathophysiological features of type 2 diabetes ( T2D ) .", "label": "", "metadata": {}, "score": "83.27315"}
{"text": "Although there was no significant change in leptin levels during exenatide treatment when we analyzed our data in aggregate , we noted that leptin levels decreased significantly among exenatide high responders compared with nonresponders .", "label": "", "metadata": {}, "score": "83.36534"}
{"text": "A1C was assayed by a method certified by the National Glycohemoglobin Standardization Program .Subjects were provided with MediSense Precision Xtra / MediSense Optium glucose meters ( Abbott Laboratories , Abbott Park , IL ) calibrated to plasma glucose to determine self - measured plasma glucose ( SMPG ) and were asked to record values in their diaries .", "label": "", "metadata": {}, "score": "83.473206"}
{"text": "Inflammatory markers .Inflammatory markers were measured using ELISA ( R&D Systems ) .They included C - reactive protein , total adiponectin , soluble intercellular adhesion molecule-1 , soluble vascular cell adhesion molecule-1 , soluble tumor necrosis factor receptor I , soluble tumor necrosis factor receptor II , and monocyte chemotactic protein-1 .", "label": "", "metadata": {}, "score": "83.47921"}
{"text": "DURATION 5 : exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes .J Clin Endocrinol Metab 2011 ; 96 : 1301 - 10 . . .", "label": "", "metadata": {}, "score": "83.65199"}
{"text": "GLP-1 analogues are an expanding drug class with the recent development of longer acting agents including the once weekly ( LAR ) form of exenatide , Bydureon .", "label": "", "metadata": {}, "score": "83.68988"}
{"text": "Not Provided .Study Type ICMJE .Interventional .Study Phase .Phase 2 .Study Design ICMJE .Allocation : Randomized Endpoint Classification : Safety / Efficacy Study Intervention Model : Parallel Assignment Masking : Double Blind ( Subject , Investigator )", "label": "", "metadata": {}, "score": "83.81639"}
{"text": "This review highlights the need to improve our understanding of the physiological mechanisms through which GLP-1 agonists act , while the results of longer term safety studies are awaited .", "label": "", "metadata": {}, "score": "83.873245"}
{"text": "Our analysis is limited by significant heterogeneity between studies , and suggests the need for more detailed investigation using more accurate measurements of heart rate than those typically used in clinical practice .", "label": "", "metadata": {}, "score": "84.32771"}
{"text": "CVD risk factors .Blood pressure and pulse were measured using a Dinamap automatic blood pressure recorder ( GE Healthcare , Tampa , FL ) .", "label": "", "metadata": {}, "score": "84.40685"}
{"text": "The combined power ( calculated as the product of the marginal powers for A1C and weight ) was at least 85 % .CIs for secondary end points were corrected using Dunnett 's test .", "label": "", "metadata": {}, "score": "84.42299"}
{"text": "P.H. and M.Z. are both employees of Novo Nordisk .No other potential conflicts of interest relevant to this article were reported .The authors acknowledge the assistance of the LEAD-4 Met+TZD Study Group , their staff , clinical trial personnel , and the subjects for participating in the study .", "label": "", "metadata": {}, "score": "84.66099"}
{"text": "GLP-1 , glucagon - like peptide-1 .Robinson LE , Holt TA , Rees K , et al .BMJ Open 2013;3:e001986 .Page 10 .", "label": "", "metadata": {}, "score": "84.882256"}
{"text": "Change in Islet Cell Yield During Culture [ Time Frame : From 0 hours pre - culture to 24 hours to 72 hours ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "85.52465"}
{"text": "We used a search strategy to capture ' exenatide ' , ' liraglu- tide ' or ' glucagon - like peptide-1 ' in any field , limited to ' Randomised ControlledTrial ' , ' ControlledClinicalTrial ' .", "label": "", "metadata": {}, "score": "85.68805"}
{"text": "Greater than 20 % attrition 10 Single blind 11 Single blind Continued 4 Robinson LE , Holt TA , Rees K , et al .BMJ Open 2013;3:e001986 .", "label": "", "metadata": {}, "score": "85.82732"}
{"text": "Y.-D.I.C. and Y.V.L. measured the inflammatory markers and edited the manuscript .G.R. designed the study and edited the manuscript .S.H.K. is the guarantor of this work and , as such , had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis .", "label": "", "metadata": {}, "score": "86.18091"}
{"text": "Drugs of the Future 26 : 677 -685 , 2001 .Diabetes Care 25 : 1398 -1404 , 2002 .Agerso H , Jensen LB , Elbrond B , Rolan P , Zdravkovic M : The pharmacokinetics , pharmacodynamics , safety and tolerability of NN2211 , a new long - acting GLP-1 analog , in healthy men .", "label": "", "metadata": {}, "score": "86.358246"}
{"text": "J.B.B. has conducted clinical trials and provided consultation for Novo Nordisk , Amylin Pharmaceuticals , and Eli Lilly under contract with the University of North Carolina ; these relationships do not provide him with direct financial benefit .", "label": "", "metadata": {}, "score": "86.45084"}
{"text": "No other potential conflicts of interest relevant to this article were reported .J.D. researched data , contributed to discussion , and wrote , reviewed , and edited the manuscript .", "label": "", "metadata": {}, "score": "86.86598"}
{"text": "Inclusion Criteria : .Type 1 diabetes mellitus for at least 5 years .Candidate for islet cell transplantation based upon local accepted practice and guidelines .", "label": "", "metadata": {}, "score": "87.15935"}
{"text": "Three levels of response could be identified .Seven high responders were randomly assigned to exenatide first .We did not identify any pretreatment metabolic parameters that predicted the degree of response to exenatide .", "label": "", "metadata": {}, "score": "87.19224"}
{"text": "Liraglutide is a long - acting , acylated GLP-1 analog , acting as a full agonist toward the GLP-1 receptor ( 15 ) .The dosing regimen is a once daily injection .", "label": "", "metadata": {}, "score": "87.70485"}
{"text": "We also undertook sensitivity analyses to investigate the influence of trial designs on het- erogeneity measures , including the background OAD treat- ment common to both arms .", "label": "", "metadata": {}, "score": "87.74129"}
{"text": "Receive free email alerts when new articles cite this article .Sign up in Collections Topic ( 108 articles)Pharmacology and therapeutics ?( 114 articles)Cardiovascular medicine ?", "label": "", "metadata": {}, "score": "87.74469"}
{"text": "18 Years and older .Accepts Healthy Volunteers .No .Contacts ICMJE .Contact information is only displayed when the study is recruiting subjects Abstract .", "label": "", "metadata": {}, "score": "87.88067"}
{"text": "Madsbad S , Kielgast U , Asmar M , et al .An overview of once - weekly glucagon - like peptide-1 receptor agonists - available efficacy and safety data and perspectives for the future .", "label": "", "metadata": {}, "score": "87.993225"}
{"text": "Insulin was measured using the access chemiluminescent assay ( Beckman Coulter , Fullerton , CA ) .Adiponectin was measured using an enzyme - linked immunosorbent assay technique ( Alpco Diagnostics , Salem , NH ) , and leptin was measured using a radioimmunoassay technique ( Linco Research , St. Charles , MN ) .", "label": "", "metadata": {}, "score": "88.08143"}
{"text": "Blood pressure We included 31 trials measuring blood pressure changes ( figures 4 and 5 ) .Body weight Twenty - one trials measuring changes in weight were included ( figure 6 ) .", "label": "", "metadata": {}, "score": "88.60093"}
{"text": "Page 5 .Table 2 No .Higher attrition in the exenatide arm 13 Open label 14 Open label .Greater than 20 % attrition .", "label": "", "metadata": {}, "score": "88.77996"}
{"text": "Ryder REJ , Thong KY , Cull ML , et al . on behalf of the ABCD nationwide exenatide audit contributors .The Association of British Clinical Diabetologists ( ABCD ) nationwide exenatide audit .", "label": "", "metadata": {}, "score": "88.84238"}
{"text": "References .Comparison of the 1997 and 2003 American Diabetes Association classification of impaired fasting glucose : impact on prevalence of impaired fasting glucose , coronary heart disease risk factors , and coronary heart disease in a community - based medical practice .", "label": "", "metadata": {}, "score": "89.14732"}
{"text": "Highlighting these similarities and differences could be beneficial for physicians in choosing the best treatment strategy for their patients .Full - text \u00b7 Article \u00b7 Jun 2014 \u00b7 European Journal of Internal Medicine Abstract .", "label": "", "metadata": {}, "score": "89.1869"}
{"text": "Lancet .2008 [ Epub ahead of print].DOI : doi : 10.1015/S0140 - 6736(08)61246 - 5 .Matthews DR , Hosker JP , Rudenski AS , Naylor BA , Treacher DF , Turner RC : Homeostasis model assessment : insulin resistance and \u03b2 - cell function from fasting plasma glucose and insulin concentrations in man .", "label": "", "metadata": {}, "score": "89.38984"}
{"text": "Literature searches .We used a search strategy to capture ' exenatide ' , ' liraglutide ' or ' glucagon - like peptide-1 ' in any field , limited to ' Randomised Controlled Trial ' , ' Clinical Trial ' or ' Controlled Clinical Trial ' .", "label": "", "metadata": {}, "score": "89.39001"}
{"text": "All GLP-1 RA meta - analyses regarding CVD actually have considerable limits because most finished and analyzed RCTs were not specifically designed to answer CVD questions .", "label": "", "metadata": {}, "score": "89.61319"}
{"text": "Diabetes Care 25 : 1398 -1404 , 2002 .Diabetes 53 : 1187 -1194 , 2004 .Diabetes Care 30 : 1608 -1610 , 2007 .", "label": "", "metadata": {}, "score": "90.02429"}
{"text": "Acknowledgements We would like to thank Amylin Pharmaceuticals and Novo Nordisk for providing us with unpublished data for this meta - analysis .Contributors LER , JPO and HSR were involved in the design and conception of the study .", "label": "", "metadata": {}, "score": "90.309326"}
{"text": "All participants gave written informed consent before participation .The study was approved by the Beth Israel Deaconess Medical Center Institutional Review Board and was conducted according to the principles expressed in the Declaration of Helsinki .", "label": "", "metadata": {}, "score": "90.64064"}
{"text": "GLP-1 is an incretin hormone produced in the gut that stimulates glucose - dependent endogenous insulin secretion , decreases glucagon secretion , slows gastric motility and emptying , and reduces appetite and food intake ( 2 , 3 ) .", "label": "", "metadata": {}, "score": "90.93572"}
{"text": "Lipoprotein concentrations were performed by the core laboratory at Stanford University Medical Center by standardized methods approved by the Centers for Disease Control and Prevention .", "label": "", "metadata": {}, "score": "91.65785"}
{"text": "Minor hypoglycemic episodes were defined as those that could be self - treated ; major episodes were defined as requiring third - party assistance or medical intervention .", "label": "", "metadata": {}, "score": "91.89396"}
{"text": "Acknowledgments .This study was supported by grant M01-RR-01032 from the Beth Israel Deaconess Medical Center General Clinical Research Center and by the Harvard Clinical and Translational Science Center ( National Institutes of Health Award UL1-RR-025758 and financial contributions from Harvard University and its affiliated academic health care centers ) .", "label": "", "metadata": {}, "score": "92.69798"}
{"text": "We acknowledge the assistance of the LEAD-2 study group , their staff , and clinical trial personnel and the subjects for participating in the study .", "label": "", "metadata": {}, "score": "93.29949"}
{"text": "55 The mean age of the participants ranged from 52.3 to 60.3 years .We , therefore , chose to report results using the random effects approach , although the differences between random effects and fixed effect results were very small .", "label": "", "metadata": {}, "score": "93.60319"}
{"text": "Data provided are for informational purposes only .Although carefully collected , accuracy can not be guaranteed .The impact factor represents a rough estimation of the journal 's impact factor and does not reflect the actual current impact factor .", "label": "", "metadata": {}, "score": "94.40951"}
{"text": "Footnotes .Contributors LER , JPO and HSR were involved in the design and conception of the study .LER and TAH conducted the bibliographic searches , identified the included papers and extracted the data independently .", "label": "", "metadata": {}, "score": "94.8649"}
{"text": "G.S.G. and M.C. researched data and reviewed and edited the manuscript .E.K.M. , E.W. , and J.M. contributed to discussion and reviewed and edited the manuscript .", "label": "", "metadata": {}, "score": "95.22892"}
{"text": "QD , every day .Acknowledgments .K.H. has received honoraria for consultation and lecturing from Novo Nordisk , sanofi - aventis , and Merck .", "label": "", "metadata": {}, "score": "95.230095"}
{"text": "KR advised on methodological issues .All authors were involved in the drafting of the manuscript .Funding This research received no specific grant from any funding agency in the public , commercial or not - for - profit sectors .", "label": "", "metadata": {}, "score": "97.75365"}
{"text": "Body mass index ( BMI ) 17 to 40 kg/ m^2 inclusive .Exclusion Criteria : .Clinically significant cardiovascular and/or cerebrovascular disease .Current ongoing symptomatic biliary disease , clinical signs or symptoms of pancreatitis , or a history of chronic or acute pancreatitis , as determined by the investigator .", "label": "", "metadata": {}, "score": "98.04589"}
{"text": "No other potential conflicts of interest relevant to this article were reported .S.H.K. helped design and conducted the research , analyzed the data , and wrote and edited the manuscript .", "label": "", "metadata": {}, "score": "98.48928"}
{"text": "In our daily practice we abbreviate this therapeutic concept with the term BIT ( basal insulin combined incretin mimetic therapy ) in a certain analogy to BOT ( basal insulin supported oral therapy ) .", "label": "", "metadata": {}, "score": "98.89128"}
{"text": "All authors were involved in the drafting of the manuscript .Funding This research received no specific grant from any funding agency in the public , commercial or not - for - profit sectors .", "label": "", "metadata": {}, "score": "101.60261"}
{"text": "The authors also thank Monika Haack , Beth Israel Deaconess Medical Center , for assistance with the measurements of sleep parameters and data analysis .Footnotes .", "label": "", "metadata": {}, "score": "101.817245"}
{"text": "Family or personal history of multiple endocrine neoplasia type 2 ( MEN2 ) or familial medullary thyroid carcinoma ( FMTC ) .Gender .Both .", "label": "", "metadata": {}, "score": "102.905106"}
{"text": "We also thank C.T. Chang for statistical assistance and Angela M. Campbell and Jennifer M. Faleska for writing assistance ( all from Novo Nordisk ) .", "label": "", "metadata": {}, "score": "104.80537"}
{"text": "BMJ Open 2013;3:e001986 .Page 17 .doi : 10.1136/bmjopen-2012 - 001986 2013 3 : BMJ Open .Louise E Robinson , Tim A Holt , Karen Rees , et al .", "label": "", "metadata": {}, "score": "105.83298"}
{"text": "Please refer to this study by its ClinicalTrials.gov identifier : NCT01733758 Type 2 diabetes mellitus ( T2DM ) is a chronic metabolic disorder characterized by progressive deterioration in the function of the pancreatic beta - cells , which are the cells that produce and secrete insulin ( the hormone primarily responsible for the handling of glucose in the body ) .", "label": "", "metadata": {}, "score": "108.80922"}
{"text": "We are indebted to the following principal investigators and their staff , who participated in the NN2211 - 1310 international study group .Norway : H. Ulrichsen , Harstad ; A. Tandberg , Bekkestua ; M. Wangestad , Oslo ; S. Madsbu , Elverum .", "label": "", "metadata": {}, "score": "110.36743"}
{"text": "Choosing to participate in a study is an important personal decision .Talk with your doctor and family members or friends about deciding to join a study .", "label": "", "metadata": {}, "score": "112.36751"}
{"text": "JPO and HSR have received research funding ( paid to Warwick Medical School ) from Novo Nordisk , and payments for speaking from Novo Nordisk .", "label": "", "metadata": {}, "score": "113.52775"}
{"text": "JPO and HSR have received research funding ( paid to Warwick Medical School ) from Novo Nordisk , and payments for speaking from Novo Nordisk .", "label": "", "metadata": {}, "score": "113.52775"}
{"text": "Talk with your doctor and family members or friends about deciding to join a study .To learn more about this study , you or your doctor may contact the study research staff using the Contacts provided below .", "label": "", "metadata": {}, "score": "115.18847"}
{"text": "Waist circumference ( cm ) was measured using a nonelastic measuring tape .Body composition was measured using bioelectrical impedance analysis ( BIA ; RJL System Quantum II Bioelectrical Body Composition Analyzer ) after an overnight fast .", "label": "", "metadata": {}, "score": "115.957855"}
{"text": "Glucagon - like peptide ( GLP)-1 is an incretin hormone secreted by the enteroendocrine L cells of the small intestine in response to food intake .", "label": "", "metadata": {}, "score": "121.060776"}
{"text": "Denmark : S. Madsbad , Hvidovre ; O. Schmitz , Aarhus ; K. Koelendorf , Koege ; H. Perrild , Copenhagen ; A. Prange , Kolding ; S. Nistrup Holmegaard , Thisted .", "label": "", "metadata": {}, "score": "123.91979"}
{"text": "The costs of publication of this article were defrayed in part by the payment of page charges .This article must therefore be hereby marked \" advertisement \" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact .", "label": "", "metadata": {}, "score": "135.3169"}
